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Abstract
A kidney transplant is the optimum treatment for patients with renal failure, both
prolonging life and improving its quality (Parfrey, 2000. Wolfe, 1999). Transplanting
an organ subjects it to Ischaemia reperfusion injury (IRI) as the vascular supply is
temporarily disrupted and then reinstated. IRI is a risk factor for delayed graft
function (DGF) (Bronzatto, 2009), which prejudices both short and long-term graft
survival (Ojo, 1997). The severity of IRI has also been linked with early changes
within the renal microvasculature that correlate with subsequent impaired organ
function and DGF following transplantation (Schmitz, 2008). At the current time
there are no specific treatments for IRI. Heme oxygenase-1 (HO-1) is a 32kDa
enzyme that catalyses the breakdown of Heme molecules to Biliverdin, Carbon
monoxide and free Iron. Studies suggest that induction of HO-1 prior to surgery may
be beneficial by reducing the severity of injury in animal models of IRI and
transplantation (Amersi, 1999. Tullius 2002). The majority of such studies utilise
heavy metal protoporphyrins as HO-1 inducing agents. These substances are highly
toxic, preventing their use in clinical practice. Heme arginate (HA) is a clinically
licensed drug used in humans for the treatment of porphyria. It is well tolerated, with
a minimal side effect profile (Mustajoki, 2003). It has also been shown that HA can
induce HO-1 in healthy human volunteers (Doberer, 2010). The principal aims of this
thesis are to determine whether the administration of HA can confer protection within
in vitro and in vivo models of IRI and renal isograft transplantation. I assess the
structural integrity of the microvasculature and evaluate changes in the inflammatory
cell populations following transplantation and IRI to determine whether these
correlate with the degree of renal tubular injury observed.
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Initial In vitro experiments demonstrate the potential for HA to induce HO-1 in a
murine cardiac endothelial cell line (MCEC-1). I subsequently develop and
characterise an in vitro model that simulates the changes in gaseous tensions
encountered during IRI in vivo, and show that MCEC-1 cells that are pre-treated with
HA are significantly protected against exposure to these adverse conditions (n=3,
p<0.05).
In subsequent in vivo experiments, HA administration was shown to up-regulate
functional HO-1 within murine renal tissue. Mice that were pre-treated with HA 24
hours prior to surgery showed significant preservation of renal tubules and renal
function (creatinine) in a murine model of renal IRI (n=8, p<0.05). In a series of
murine renal isograft transplants, HA pre-treatment of organ donors resulted in
significant protection of renal tubules against IRI (n=10, p<0.05). An apparent, but
statistically insignificant, trend toward protection of renal tubules was also observed
in organ recipients that were pre-treated with HA (n=10, p=0.21). Further experiments
are necessary to clarify the underlying mechanisms responsible for the apparent
protective effects ofHA against tubular injury in vivo.
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Organ transplantation represents one of the major success stories in medicine and
surgery in the 20th century. A wide variety of organs including hearts, livers, lungs,
small bowel and skin can now be transplanted successfully and offer clinical benefits
to recipients. Worldwide, the kidney is the most commonly transplanted organ.
According to the website UKTransplant.org.uk, 1751 renal transplants were
performed in the UK between 1st April 2012 and 31st March 20131 As of the 30th of
June 2013, 7256 patients were on the waiting list for an organ transplant, 6017 of
whom required a kidney1. The first kidney transplant in the UK took place between a
pair of identical twins in Edinburgh in I9602. A renal transplant remains the gold
standard treatment for end stage renal failure (ESRF) which can be defined as a
glomerular filtration rate (GFR) of less than 15ml per min per 1.73m2 or a patient who
is on dialysis. The UK renal registry from 2009 estimates that over 47000 people
received renal replacement therapy (RRT) in the UK3. RRT is a supportive therapy
rather than a definitive treatment for ESRF and is associated with significant
complications including hypotension4, arrythmias5, myocardial ischaemia6, problems
7 *8 *9 • ••of vascular access , pulmonary hypertension , depression and septic complications
including endocarditis10 and oseteomyelitis11. Renal transplantation both prolongs
life12 and improves the quality of life for recipients13. It is also a more cost effective
treatment than long-term hemodialysis14. A factsheet published by the Organ
Donation and Transplantation directorate (formerly UK transplant) states that the cost
benefit of transplantation compared to haemodialysis over a 10 year period (the
median transplant survival time) is £24,100 per year for each year that the patient has
a functioning transplant1. The medical and economic benefits to receiving an organ
transplant are substantial. Despite proactive campaigns to improve donation rates,
there remains a shortage of organs for implantation. As of March 2013 only 31% of
the adult UK population are on the organ donor register1. Such shortages have
2
compelled the use of organs from "expanded criteria donors" including patients of
advanced age or those with co-morbid conditions such as obesity, diabetes or
hypertension. In 2012-2013 the number of deceased kidney donors increased by 11%
to 1148 compared to the previous year1. Of these donors the proportion aged 70 years
and over increased from 2 to 12%, whilst the proportion that were clinically obese
(Body Mass Index of 30 and over) increased from 16 to 26% when compared to 2011-
20121. Organs donated from such sources are potentially of poorer quality and may
negatively impact graft survival and function15"18. Chronic graft injury remains a
significant clinical problem that is influenced by a variety of immunological and non
immunological processes19. In the UK in 2009, 2.9% of prevalent transplant patients
experienced graft failure, a figure which has remained almost constant since 200320.
Graft loss has major implications for patients as it necessitates either a return to
dialysis or a further transplant procedure, which carries an inherent risk of morbidity
and mortality. Moreover, a repeat transplant further depletes the number of donor
organs available to other recipients. There is a clear need to develop appropriate
strategies to address modifiable risk factors associated with graft loss. Ischaemia
2i
reperfusion injury (IRI) is associated with delayed graft function (DGF) , which in
turn has been reported as an independent risk factor for acute rejection22 and chronic
91 • •
graft loss . Progress in the field of transplantation has necessitated important
advances in surgical techniques and has lead to improvements in the understanding of
key immunological processes. Managing organ rejection has remained an important
challenge for basic scientists and transplant surgeons alike. Despite many
improvements in therapies for rejection, there remains no treatment for IRI at the
current time. In this thesis I shall evaluate the capacity of Heme arginate, an inducer




Ischaemia Reperfusion Injury (IRI) is encountered when the blood supply to an organ
or tissue is temporarily disrupted and then reinstated. IRI has been implicated in the
pathogenesis of a wide range of medical and surgical conditions including trauma,
myocardial infarction, sickle cell disease, ischaemic stroke, acute kidney injury,
multiple organ failure and compartment syndrome 24~26. However, the most obvious
and predictable examples of IRI are to be found within the field of transplantation
surgery. Donor organs become ischaemic while they are retrieved and stored prior to
implantation. Following successful transplantation, restitution of the blood supply to
the organ results in reperfusion injury.
Ischaemia reperfusion injury is a complex phenomenon in which tissue damage is
caused by a wide range of pathological processes. IRI results in vascular leakage27
28 • 29and activation of cell death programs that result in tubular apoptosis and necrosis .
IRI also leads to activation of the innate30 and adaptive31 arms of the immune system,
transcriptional reprogramming32, auto-antibody33, complement34 and platelet
activation35 as well as the "no-reflow" phenomenon that further may potentiate tissue
ischaemia36.
Ischaemic phase
As the name suggests, IRI is composed of an ischaemic phase that is subsequently
followed by a reperfusion phase. The following biochemical changes occur in both
renal tubular epithelial and endothelial cells. During the ischaemic period, aerobic
metabolism is disrupted resulting in a reduction in oxidative phosphorylation. ATP
synthesis falls, resulting in disturbances in cellular ion homeostasis, partly due to
impaired membrane pump activity. In addition there is activation of hydrolase
enzymes that causes an increase in the permeability of cellular membranes. The
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intracellular pH falls as H+ ions are liberated from damaged lysosomes, in addition
there is an increase in the rate of glycolysis and ATP degradation due to anaerobic
metabolism. Several processes seek to regulate this change in pH and result in a
number of biochemical changes that are deleterious for renal tubular cell survival.
There is an increase in cytosolic Na+ and Ca2+ concentrations as activity of the Na+/K+
adenosine triphosphatase (ATPase) falls. In addition there is increased exchange of
Ca2+ for Na+ by the Na+/Ca+ antiporter and the permeability of the plasma membrane
increases. This is exacerbated by elevated cytosolic Na+ concentrations that result in
osmotic swelling leading to disruption to the plasma membrane and cell necrosis,
29
provoking an immunological reaction . Increased intracellular calcium
concentrations result in the activation of hydrolases such as phospholipases (e.g
phospholipase A2) and proteases that further degrade cytoskeletal proteins. Elevated
plasma Ca2+ concentrations alter the mitochondrial membrane potential, whilst Ca2+
ions accumulate within the mitochondrial matrix. These changes may cause a
transition pore to form within the mitochondrial membrane, allowing cytosolic ATP
to gain access to the mitochondrial ATPase. This results in the further depletion of
cellular ATP. During the ischaemic period, cell death occurs also occurs by apoptosis.
This process is less immunostimulatory than necrosis as the cell membrane largely
remains intact37, however extracellular release of ATP from apoptotic cells through
pannexin hemi-channels does occur and may attract phagocytic cells38. Some
evidence suggests that inhibition of apoptosis may be protective murine renal IRI39.
Tubuloglomerular feedback
One of the physiological processes by which the kidney responds to ischaemia is
through tubuloglomerular feedback (TGF). Renal blood flow and GFR are maintained
within relatively narrow limits by hormonal influences and by efficient autoregulation.
Increases in renal blood flow cause parallel increments in GFR, thereby increasing the
5
necessity of tubular reabsorption and consequently increasing the metabolic and
Oxygen demands of renal tissues. In the context of ischaemia, a high GFR may
therefore potentiate the tissue damage sustained. Physiological coordination between
renal blood flow and GFR with tubular reabsorption is maintained by the TGF system.
The macular densa, a collection of densely packed epithelial cells at the junction of
the thick ascending limb of the loop of Henle and the distal convoluted tubule, detects
the concentration of NaCL via an apical Sodium -Potassium co-transporter. A high
concentration of NaCL signifies an elevated GFR and vice versa. In response to
elevated NaCL concentrations, i.e. elevated GFR. ATP is released from cells of the
macular densa through pannexin channels. This extracellular ATP is converted to
adenosine, which binds to Adenosine A2 receptors on extraglomerular mesangial cells,
triggering a rise in intracellular calcium levels40. This calcium signal is then
propagated via gap junctions to adjacent cells, including granular cells of the
juxtaglomerular apparatus and vascular smooth muscle cells of the afferent arteriole,
resulting in afferent arteriole vasoconstriction and a decrease in renin release41. Both
of these changes tend to decrease GFR and therefore the requirement for active
tubular resorption of filtered solutes, thus reducing the Oxygen requirements of renal
tissues.
Reperfusion phase
During the reperfusion stage of the injury, post ischaemic kidneys are subjected to a
robust inflammatory process which involves both the innate and adaptive arms of the
immune response with endothelial activation, leukocyte recruitment, upregulation of
chemokines and cytokines, and activation of the complement system. Reconnection of
the blood supply exposes previously ischaemic tissues to increased concentrations of
oxygen (O2). This results in the generation of reactive oxygen species (ROS) as the
enzymes of the mitochondrial respiratory chain which were proteolyticaly damaged
6
during the ischaemic period transfer electrons onto oxygen molecules. These ROS
cause direct injury to cellular proteins and also result in activation of endothelial cells
with upregulation of P-Selectin42 and E-Selectin43, and the adhesion molecules
ICAM-144, VCAM-145, and PECAM-146. IRI stimulates the synthesis of pro¬
inflammatory cytokines such as IL-1, IL-6 and TNF-a47. Blockade of IL-1 and IL-6
has been shown to be protective in murine renal IRI48. As a result of enhanced
cytokine production and endothelial activation, there is increased recruitment,
margination, rolling (P-Selectin) and adherence (ICAM-1, VCAM-1) of neutrophils
and other leucocytes to the endothelial surface. There is also enhanced diapedesis via
PECAM-1 with leucocytes crossing the endothelium and entering the tissues. These
leucocytes may play a key role in IRI. Macrophages are recruited to the post capillary
venules of the outer medulla following renal IRI49' 50 and have been shown to
contribute to the initiation of ischaemic acute renal failure in rats51. Activated
macrophages may cause tissue injury via a variety of mechanisms such as the
production of pro-inflammatory TNF a, induction of apoptosis, recruitment of
neutrophils and elaboration of proteolytic enzymes that cause tissue injury. Indeed,
evidence suggests that IRI is abrogated in animal models where macrophages are
depleted52 Other leukocytes such as neutrophils are also implicated in the
pathogenesis of IRI. Anti-ICAM-1 antibody protects wild type but not neutrophil
depleted mice from renal IRI53. The precise nature of this role is somewhat
controversial however, and other authors have failed to demonstrate a protective
effect of neutrophil depletion within in vivo models of renal IRI54. Neutrophils may
be injurious by physically impeding blood flow due to their presence in increased
numbers within the microvasculature or by production of harmful ROS and elastases.
Other cell types that may play a deleterious role in renal IRI include natural killer
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(NK) cells 55 and natural killer T (NKT) cells possibly through their capacity to recruit
neutrophils56.
Complement
The complement system plays a role in both innate and adaptive immunity in the
defence against microbial pathogens. Activation of complement via the classical57 and
alternate58 pathways has been implicated in the pathogenesis of renal IRI. The
complement system may become activated in response to acute phase serum proteins
such as C-reactive protein and complement mediated recognition of damaged cells,
further stimulating the recruitment of inflammatory cells to sites affected by IRI59.
Whilst studies in animals suggest that IRI may be attenuated by inhibition of specific
components of the complement cascade57'58, clinical studies have not replicated these
results60'61. The complement system may in fact play a dual role in IRI, with one
study of murine hepatic IRI suggesting that whilst excessive activation of the system
is detrimental, a threshold level of complement activation is necessary for liver
regeneration and repair34.
Coagulation
IRI stimulates platelet aggregation62 and the release of platelet derived mediators that
further exacerbate injury63. Platelet activation may occur in response to integrin
exposure at the basement membrane following cellular injury64 or by transportation of
platelets across epithelial barriers in association with infiltrating neutrophils65. The
resulting microthrombi may physically impede blood flow in small vessels thereby
exacerbating downstream ischaemia66. In addition, platelets release inorganic
phosphate polymers of 60-100 phosphate residues that activate plasma protease factor
XII and act in a pro-coagulant and pro-inflammatory fashion63. A pathophysiological
role for platelets within IRI is supported by a study involving Kindlin 3 deficient mice
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in a model of mesenteric IRI64. Kindlin 3 is a protein that plays a role in integrin
mediated platelet activation. Animals in which this gene was deleted were protected
against mesenteric IRI and showed virtually no platelet adherence to injured vessel
walls following injury. Protection of renal function has also been associated with
reduced platelet deposition in a murine model of renal IRI67. In this study mice were
injected with HO-1 over-expressing macrophages that homed to the site of injury
following IRI. Such functional protection may relate to improved renal perfusion due
to carbon monoxide (a bi-product of HO-1 metabolism) related vasodilatation and
inhibition of platelet aggregation. Similar mechanisms have also been implicated in
clinical transplantation68.
Implications of IRI for short and long-term graft survival
The influence of the ischaemia reperfusion injury (IRI) sustained by the organ graft at
the time of surgery on long-term graft survival remains a matter of some debate69. IRI
is established as a significant cause of acute kidney injury70 and studies have shown a
correlation between the severity of IRI at the point of organ implantation and the
incidence of delayed graft function (DGF)21' 22. DGF is a common post-operative
complication following organ transplantation. In the context of renal transplantation,
DGF has traditionally been defined as a requirement for dialysis during the first post¬
operative week except where necessary for the management of hyperkalemia71.
However, more objective and functional definitions of DGF have been proposed.
Functional delayed graft function (fDGF) is defined as a failure of the serum
creatinine to decrease by at least 10% on 3 successive days during the first week
following renal transplantation. Both traditionally defined DGF and fDGF have been
shown to represent an early markers of subsequent inferior allograft outcomes ' .
DGF is particularly associated with elderly73, marginal7 ' 75 and cadaveric organ
76 • • 22donors . The incidence of delayed graft function varies between centres , but has
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been shown to affect between 8 and 50% of organ transplants in the USA23'11.
Delayed graft function itself is a significant clinical problem that is associated with a
prolonged hospital stay15, increased economic costs78 and a requirement for further
dialysis in some cases21. Moreover, DGF may have implications for long-term
outcomes following organ transplantation. Ojo et al have shown DGF to be an
independent negative prognostic factor for renal allograft survival at 5 years23. In this
study, significantly fewer allografts with DGF but no evidence of acute rejection
survived to 60 months post transplant compared with grafts that exhibited neither
acute rejection nor DGF. However, the mechanism underlying this association and the
relative contribution of immune priming or injuries to the tubular and endothelial
compartments remains uncharacterised. Requiao-Moura et al22 evaluated a group of
628 patients that underwent deceased donor renal transplantation in Brazil between
2002 and 2005. These authors found a correlation between DGF and acute rejection
events as well worse graft function and lower graft survival rate at one year. Other
authors have also shown DGF to be associated with an increased risk of acute
• • • 21
rejection and reduced graft function and survival after one year . However, some
studies question whether a direct link exists between delayed graft function and
subsequent chronic graft dysfunction. Boom et al79 found DGF to be associated with a
prolonged cold ischaemia time in a study of 734 cadaveric renal transplants performed
between 1983 and 1987. These authors also noted an association between DGF and
both acute rejection and suboptimal function at one year, but, in contrast to the
findings of Ojo et al, found no independent association between DGF and chronic
graft loss. Work by Troppmann et al suggested that whilst DGF in isolation has no
direct association with late graft failure80, DGF when combined with acute rejection at
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one year was associated with late graft loss . The link between DGF and acute
rejection at one year appears to be consistently established across these studies, as is
an association between acute rejection and chronic graft loss. Whilst the independence
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of DGF as a risk factor for late graft loss is a matter for debate, there is agreement
about the association between the severity of IRI and DGF. Interest has focussed upon
strategies that seek to limit the severity of IRI following transplantation as a means of
improving the short and long-term outcomes following solid organ transplantation.
Current Strategies to limit Ischaemia Reperfusion Injury
The introduction of new and highly effective immunosuppressive therapies has
resulted in a dramatic reduction in acute rejection rates in recent years; however,
whilst a number of measures seek to minimize the impact of IRI, no specific
treatments for the phenomenon are currently available. Several strategies have
achieved some success in minimizing the extent of the injury caused by IRI and these
are briefly summarised below.
Ex vivo normothermic perfusion
Ex vivo normothermic perfusion (EVNP) is an emerging technique that attempts to
improve the outcome following solid organ transplantation by minimizing IRI. EVNP
involves the active, mechanical perfusion of individal organs ex vivo with
preservation solutions maintained at normal body temperatures prior to implantation.
This is in contrast to static cold perfusion in which organs are stored in cold
preservation solutions (i.e in immobile preservation fluid, without mechanical
perfusion). The technique has been shown to result in improved renal function and
lower levels of tubular injury when compared with static cold stored kidneys in a
porcine model of renal transplantation82. Organs that received EVNP in this study
showed reduced expression of the inflammatory cytokines TNFa, IL-113 and IL-8 but
increased expression of IL-6 when compared with the static cold stored organ group.
The technique has undergone clinical trials in human transplant patients where it has




kidney donors Organs treated with EVNP have been shown experimentally to have
higher ATP levels when compared to cold stored organs, which may potentially
84
explain the beneficial effects of the technique
Preservation solutions
Organ preservation solutions were developed for the storage of organs prior to
implantation. Examples of such solutions include Viaspan, also known as University
of Wisconsin (UW) solution, histidine-tryptophan-ketoglutarate (HTK) solution and
Celsior solution. UW solution contains a variety of substances that aim to counteract
various elements of the injurious metabolic cascade associated with IRI. The solution
was developed to maintain an osmotic concentration by the use of metabolically inert
substances like lactobionate and raffinose rather than glucose. UW solution also
contains Hydroxyethyl starch to prevent oedema during the ischaemic phase of IRI
and free radical scavengers such as Glutathione to counter the generation of ROS
produced upon organ reperfusion. In addition, UW solution contains Monopotassium
phosphate, Magnesium sulphate, adenosine and Allopurinol. UW has been reported
to increase the time period for which organs such as liver, kidney and pancreas can be
stored prior to implantation85. The effectiveness ofUW solution has been examined in
a number of clinical and laboratory based trials and has been found to have a similar
safety and efficacy profile to Celsior solution86'87. UW is used as the storage medium
for organs in the model of murine renal isograft transplantation employed in this
thesis.
Ischaemic and remote preconditioning
Other strategies aim to increase an organ's tolerance to ischaemia in order to limit the
effects of IRI. This may be achieved by deliberately exposing tissues to multiple,
shortened periods of ischaemia followed by reperfusion prior to subsequent
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transplantation or exposure to a more prolonged period of ischaemia. Such measures
are termed "ischaemic preconditioning". Clinical trials of ischaemic preconditioning
in human patients have shown some promising results in liver transplantation88 and in
liver resection89, although the protective benefits observed in these studies are not as
striking as those seen in animal models. The underlying protective mechanisms
behind ischaemic preconditioning are thought to be multi-factorial, but may involve
the induction of the enzyme Heme oxygenase-1 (HO-1)90' '. HO-1 is an enzyme that
catabolises Haem rings to Carbon Monoxide (CO), Biliverdin and free Iron.
Interestingly some studies demonstrate protection even when the organ itself is not
directly exposed to periods of ischaemia. Subjecting the hind limbs of rats to periods
of intermittent ischaemia has been shown to confer hepatic protection in a model of
liver IRI92. This strategy has been termed "remote ischaemic conditioning". HO-1 has
again been implicated in the mechanism of this protection93. Remote Ischaemic
preconditioning has been shown to reduce hepatocellular injury in animals undergoing
hepatic IRI, and to improve sinusoidal blood flow by increasing sinusoidal diameter94.
A potential explanation for this vasodilatation may be increased carbon monoxide
production as a bi-product of enhanced HO-1 activity. Ischaemic preconditioning has
been trialled in human patients undergoing major liver resection. It was shown to
OQ
protect against post-operative liver injury in non cirrhotic patients . Remote
ischaemic preconditioning has been evaluated as an additional therapy prior to
percutaneous coronary artery angioplasty. The technique increased myocardial
salvage following angioplasty95. A form of remote ischaemic conditioning has entered
clinical trials in human patients. The REPAIR trial (Renal Protection Against
Ischaemia-Reperfusion in transplantation) is currently underway in 7 transplant
centres in the UK. Investigators are assessing a group of 406 living donor renal
transplant patients. Both the donor and recipient are randomised to receive either 3
cycles of 5 minutes of inflation of a blood pressure sphygmomanometer cuff on their
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upper arm followed by 5 minutes of rest or a placebo treatment. This intervention
takes place 24 hours prior to transplant surgery. The primary objectives of the study
will be to assess whether this has an impact on GFR 12 months after transplantation.
Secondary objectives will be, amongst others, to study whether the intervention
affects the rate of fall in creatinine in the first 72 hours after transplantation, the
inflammatory response to surgery in the first 5 post-operative days, kidney fibrosis 6
months after trasnplantation and patient outcomes 2-5 years after organ
transplantation using renal registry data. At the time of writing the results are
unknown.
Pharmacological strategies
A more common focus of experimentation has been the use pharmacological agents to
ameliorate IRI. A variety of drug treatments have been used with the intent of
influencing the various pathways that are implicated in IRI, and these pre-treatment
strategies have achieved differing degrees of success in animal models96"98
Unfortunately however, no treatment has as yet been shown to reduce mortality
significantly in human patients. This may reflect the fact that the aetiology of acute
kidney injury (AKI) is multi-factorial, complex and incompletely understood99.
Clearly, although the mechanisms of IRI responsible for AKI may be similar to those
involved in organ transplantation, the clinical context in which the IRI occurs in these
two scenarios differs. Transplantation is a planned, predictable event and therefore
provides greater possibilities for the use of pharmacological "preconditioning"
strategies that aim to reduce the damage sustained following subsequent IRI, in
contrast to "treatment strategies" that seek to ameliorate an established injury. I shall
discuss pharmacological preconditioning strategies in a subsequent section. Broadly
speaking, "treatment strategies" tend to fall into one or more main categories,
reflecting the underlying pathophysiology of IRI.
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Antioxidants and ROS scavengers
A range of antioxidant molecules have been utilised in an attempt to reduce the
cellular and protein damage induced by ROS. Lee et al100 have demonstrated that the
antioxidant ascorbic acid (vitamin C), administered following surgery, attenuated
structural and functional injury in a canine model of renal auto-transplantation. Other
authors have noted protective benefits in rat models of renal IRI following treatment
with the free radical scavenging agent Edaravone101, the inducible nitric oxide
• •109
synthase (iNOS) inhibitor Aminoguanidine and the amino acid Taurine (which has
antioxidant activity)103. Of interest, two clinically licensed anti hypertensive drugs,
Cavedilol1 4' 5 and the angiotensin-converting enzyme (ACE) inhibitor zofenopril106
have been shown to attenuate renal IRI in animal models, whilst reducing measures of
oxidant activity. Despite their recognized side effects, such drugs have the potential to
translate into practical therapies. Unfortunately no clinical trials have yet reported
benefits of similar therapeutic strategies in human patients. Although a preliminary
report has suggested early benefits of antioxidant supplementation in a small case
series of renal transplants10 , other studies have demonstrated a lack of benefit from
i • 108such agents in the long-term .
Inhibitors of apoptosis
Reduction in the amount of cell death, through inhibition of apoptosis, has also been
proposed as a therapeutic strategy in renal IRI and a variety of drugs have been
investigated in animal models. Caspases are a family of cysteine proteases that play
essential roles in apoptosis, necrosis and inflammation109. Caspase inhibitors are
effective in reducing renal injury in animal models of IRI110' 111 and pancaspase
inhibitors have entered early clinical trials in human patients112. Minocycline, a
tetracycline antibiotic which inhibits apoptosis via attenuation of TNFa has been
shown to reduce tubular cell apoptosis113, renal inflammation114 and microvascular
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permeability114 in rat models of renal IRI. Other potentially therapeutic anti apoptotic
agents include poly ADP-ribose polymerase (PARP) inhibitors'13 and p53 inhibitors
such as Pifithrin-a"6. Activated protein C (APC), an anticoagulant generated by the
thrombin-thrombomodulin complex in endothelial cells, has been shown to have an
anti apoptotic and anti-inflammatory effect"7, "8. It has been demonstrated that APC
reduces renal IRI through inhibition of leukocyte activation"9.
Growth factors
Erythropoietin (EPO) is a glycoprotein hormone that promotes erythropoiesis.
Exogenous administration of EPO has been shown to attenuate AKI in rats by
reducing tubular apoptosis and necrosis120' 121. EPO also promotes the mobilisation
and proliferation of endothelial progenitor cells from the bone marrow and these cells
have been shown to participate in tissue repair122'123. Recombinant EPO is licensed
and used in clinical practice, meaning that such findings have some potential to
become practical therapies.
Endothelin-1 antagonists
Endothelin-1 (ET-1) is a potent vasoconstrictor that is upregulated in conditions of
ischaemia124 and has been implicated in the pathogenesis and potentiation of renal
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IRI .ET-1 may also play a pro-inflammatory role in renal IRI by stimulating the
upregulation of adhesion molecules and the production of cytokines from
leukocytes126. The endothelin receptor antagonist, tezosentan, has been shown to
protect renal function in a rat model of renal IRI127. ET-1 inhibition may represent an
appropriate target for pharmacological interventions aimed at ameliorating renal IRI.
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Anti-inflammatory drugs
Leukocytes including neutrophils, monocytes, macrophages and T cells play
important roles in renal IRI, and several drugs have shown potential to ameliorate
renal IRI through an anti-inflammatory action. Many of these agents are already
licensed in human patients and are well tolerated, increasing their potential for
translation into practical therapies. Such drugs include sphingosine 1-phosphate (SIP)
analogs such as FTY720. SIP is a ligand for a family of G protein coupled endothelial
differentiation gene receptors that regulate a diverse range of cellular signalling
processes including cell survival, apoptosis, cell adhesion and movement128. FTY720
acts as a SIP agonist, leading to sequestration of lymphocytes in secondary lymphatic
tissue129. FTY720 produced lymphopenia and resulted in tissue protection in a murine
model of renal IRI130. Selective adenosine agonists have also been proven to be
protective in animal models of renal IRI. Adenosine normally binds to members of the
G protein-coupled receptor family and regulates a wide variety of physiological
processes including elaboration of ROS by neutrophils and leukocyte adherence to
endothelial cells131. The selective A2A agonist ATL146e is highly effective against
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renal IRI in rodent models . Other authors have demonstrated that pre-treatment of
mice with the steroid dexamethasone can prevent structural and functional damage in
• • • 111 • •
a model of ischaemia reperfusion injury . This protection was associated with
attenuation of inflammation. Mechanistic studies confirmed that dexamethasone
promoted activation of the glucocorticoid receptor in this model by which it attenuates
P13K/AKT activation and consequently the inflammatory response. Infliximab, a
chimeric monoclonal antibody against TNF a, is commonly used in the clinical
management of autoimmune diseases, such as Crohns disease, ulcerative colitis and
rheumatoid arthritis. Administraion of Infliximab prior to reperfusion has been shown
to reduce both structural injury and inflammation in a rat model of IRI134.
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Other classes of drugs with potential to ameliorate renal IRI include inducible nitric
oxide synthase inhibitors135 and fibrates which bind to peroxisome proliferator-
activated receptors (PPAR), suppress NF-kB activation, chemokine expression and
neutrophil infiltration136.
The Heme oxygenase system
The heme oxygenase enzymes catalyse the degradation of heme molecules into
carbon monoxide (CO), biliverdin and free iron (Fe2+). Heme oxygenase exists as
three distinct isoforms in human beings, Heme oxygenase-1, 2 and 3 (HO-1, 2 and 3).
HO-1 and HO-2 are the most prevalent forms of the enzyme. HO-2 has a molecular
weight of 36kDa, and is expressed constitutively in the liver, Leydig cells of the
testis137 and kidney138. Recent evidence suggests that HO-2 may be inducible to a
certain extent in myocardium in response to prolonged periods of hypoxaemia139. HO-
2 is thought to play an essential role in maintaining renal haemodynamics and
function138. HO-2 deficiency has been associated with major renal morphological
injury and impaired renal function in diabetic mice140. The final isoform to be
discovered, HO-3, was characterised in the 1990s. McCoubrey et al reported the
presence in rats of a 2.4kb transcript encoding a 33kDa protein141. HO-3 transcript
was detected in a series of organs including spleen, liver, kidney and brain141. HO-3
remains the most elusive and poorly understood HO isoform. Although HO-3 mRNA
is reported to be present in rat tissues141' 142, its protein expression has not been
detected at tissue level. Work by Hayashi et al143 suggested the presence of two HO-3
pseudogenes in rats, tentatively named HO-3a and HO-3b. These authors concluded
that these may be derived from HO-2 transcripts and that they were not associated
with expression of a functionally active protein.
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The first of the Heme oxygenase isoforms to be characterised and the most
extensively studied is HO-1. Tenhunen et al144 in 1968 were the first investigators to
present evidence of a previously undescribed enzyme system in microsomes capable
of degrading heme to bilirubin. The enzyme has generated much interest over recent
years following reports of its cytoprotective capacity145. Evidence has accumulated
that HO-1 may play a role in a number of disease states. Some studies have suggested
that GT repeat polymorphisms within the gene's promoter region may increase the
quantitative level of HO-1 activity in response to a given stimulus. This in turn may
be linked to a more favourable prognosis in a number of clinical conditions including
abdominal aortic aneurysm146, ischaemic cerebrovascular events147, hypertension148
and ischaemic heart disease149. Specifically, such polymorphisms have been
associated with improved outcome following renal transplantation150'151, but this has
not been reproduced in all population studies152' 153. Diminished levels of HO-1
expression may also be pathological. Kawashima et al154 report an autopsy
examination performed on a six year old boy with the only recorded case of HO-1
deficiency. The boy was born to parents each of whom had diminished HO-1 levels.
He presented clinically with signs of growth retardation, anaemia, leukocytosis,
thrombocytosis, coagulopathy, elevated serum haptoglobulin, ferritin and heme in
serum. A low serum bilirubin and hyperlipidaemia were also noted. At autopsy,
amyloid deposits were identified in the liver and adrenal glands. Fatty streaks and
fibrous plaques were also present in the aorta, an unusual finding in such a young
patient. There are some similarities between these findings and the phenotype of HO-
1 knockout mice. However, the human case seemed to disproportionately involve
endothelial cells and the reticuloendothelial system, resulting in intravascular
haemolysis, disseminated intravascular coagulation and amyloidosis. By contrast,
HO-1 deficient mice survive for relatively longer periods and are predominantly
affected by disorders of iron metabolism155.
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HO-1 is a 32kDa enzyme encoded by the HMOX-1 gene that is located on the long
arm of chromosome 22 at position 13.1156. The gene contains 5 exon regions and
spans approximately 14kb. Work by Alam et al157'158 has identified the presence of
two promoter regions that confer responsiveness to most inducers in the mouse HO-1
gene. These regions have been termed El and E2 (enhancer region 1 and 2
respectively). The mouse HMOX-1 gene is thought to share a high degree of
homology with the human form of the gene, and regions similar to these have been
found within the human HO-1 promoter139' 16°. A further enhancer region within the
human HO-1 gene itself is also involved in heme and cadmium mediated HO-1
induction161. HO-1 is induced by a wide variety of stimuli, a common characteristic of
these inducers being their capacity to cause oxidative stress l60'162"164. HO-1 catalyses
the breakdown of heme rings at the a-methene bridge to liberate carbon monoxide
2+
(CO), free iron (Fe ) and biliverdin, the latter is subsequently reduced by biliverdin
reductase to bilirubin. Rapid metabolism by HO-1 of the heme molecules produced
following IRI prevents the generation of harmful reactive oxygen species via the
Fenton reaction165. Pharmacological induction of HO-1 or substitution with the end
products of the reaction catalysed by HO-1 has shown some potential to be protective
in animal models of IRI166'167 However, other studies using metal protoporphyrins as
HO-1 inducing agents have demonstrated a worsening injury168. Preconditioning
strategies that utilise pharmacological inducers to upregulate HO-1 prior to organ
implantation have been reported to protect in animal models of hepatic169, renal170 and
cardiac transplantation171. Such data has stimulated interest in a potential role for
HO-1 in ameliorating transplant-associated IRI in human patients. At the time of
writing, no clinical trials have been undertaken using HO-1 inducing agents in human
transplant patients. The majority of animal studies published so far utilise heavy metal
protoporphyrins as HO-1 inducing agents. Such reagents are not licensed for use in
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human patients, limiting their capacity for such work to form the basis of practical
therapies.
The therapeutic benefits of HO-1 induction are mediated through the end products of
the reaction that it catalyses. Each of these substances impacts on a variety of
injurious pathways and mediators associated with IRI. This has led some authors to
speculate whether the heme oxygenase system may represent an evolutionarily
conditioned defence mechanism in human beings172. Carbon monoxide (CO)
promotes vasodilatation by acting through guanyl cyclase/cGMP and activation of
potassium activated cellular channels173. It is also anti-apoptotic in endothelial cells
and leukocytes through activation of p38 MAPK174, and attenuates ICAM -1
expression by inhibiting NFKB. CO derived from enhanced HO-1 activity inhibits the
activity of NADPH oxidase thereby suppressing the overproduction of superoxide
radicals (02-) and the accumulation of reactive oxygen species in lipopolysaccharide
stimulated macrophages. Bilirubin is a potent anti-oxidant, countering the deleterious
action of reactive oxygen species generated during ischaemia. Free iron generated by
HO-1 activity is rapidly removed through post-transcriptional upregulation of ferritin.
This has the additional benefit of sequestering other Fe2+ ions in the milieu preventing
the production of harmful ROS via the Fenton reaction. The Fe2+ liberated by HO-1
also activates the ATPase Fe2+ secreting pump, which decreases the intracellular free
Fe2+ content. Importantly, bilirubin and the depletion of free iron have been shown to
inhibit the ability of pro-inflammatory cytokines such as TNFa and IL-1(3 to induce
the expression of the adhesion molecules E-selectin, P-Selectin, ICAM-1 and VCAM-
1 via inhibition of NF kappa B175. These adhesion molecules are associated with
endothelial activation and facilitate the binding of leucocytes to the endothelium,
where their harmful effects are exerted.
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A wide range of stimuli and clinical conditions result in increased HO-1 expression
including transplantation itself176. However, it seems likely that this increase is either
too little or too late to afford maximal protection against the severity of ischaemia
reperfusion injury encountered in transplantation. Strategies aim to induce over-
expression of HO-1 to prevent transplant associated injury work by "preconditioning"
tissue such that HO-1 is already increased at the time-point at which the ischaemia
reperfusion injury occurs. Cells and tissues within the transplanted organ are likely to
be particularly vulnerable to injury in these initial stages, when they produce
insufficient HO-1 to counter the ischaemia reperfusion injury to which they are
exposed.
Heme arginate
A growing body of literature suggests that over-expression ofHO-1 may be protective
in animal models of IRI168' 169' 177' 178 and transplantation170' 171' 179. As mentioned
previously, the majority of such studies utilise metal protoporphryins as HO-1
inducing agents. These substances have numerous toxic side effects and are unstable
at physiological pH, making them unsuitable for use in humans. Heme arginate (HA,
Normosang TM, Orphan Europe) is a clinical grade heme protoporphyrin licensed in
the treatment of porphyria180' 18'. The drug is generally well tolerated clinically,
although a case report of anaphylaxis attributed to HA has been published182. The
British National Formulary lists the principal side effects of HA as fever and
thrombophlebitis at the injection site. A recent clinical study has demonstrated that
HA treatment upregulates HO-1 in healthy human volunteers, providing further
validation for its potential use in clinical trials183. In vivo studies that utilise HA are
scarce but appear to offer further evidence of the protective benefits of this drug. HA
improved liver microcirculation and mediated an anti-inflammatory cytokine response
in a rat model of simulated haemorrhagic shock184. Work from within our own group
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has shown that HA pre-treatment reduces structural injury and preserves renal
function in aged mice subjected to renal IRI50. In this thesis I shall evaluate the
capacity of HA to upregulate HO-1 and ameliorate IRI within in vitro and in vivo
models. Given its favourable safety profile and capacity to induce HO-1 in humans,
HA treatment has clear potential to translate into a practical clinical therapy.
Donor vs. recipient preconditioning strategies
The majority of studies that use preconditioning agents in models of transplantation
concentrate on treatment of the organ donor, rather than the organ recipient.
Translating this work into human patients poses a number of practical and ethical
• i • 185considerations . Although the pre-treatment of brain dead organ donors is already
well established with regard to thyroid hormones186 and metyhlprednisolone187, these
therapies function to stabilize the organ donor's clinical condition and correct the
endocrine abnormalities that occur after brain stem death. By contrast, administration
of an agent to the organ donor with the sole intent of optimizing that donor's organs
for transplantation is deemed less ethically acceptable. Any preconditioning measure
employed in such a manner may also have implications for the functioning of the
donor's other organs and may influence their suitability for transplantation. Systemic
treatment of the organ donor may not be practical unless it can be demonstrated that
such measures at least do not adversely affect the outcome following transplantation
of the other organs. Such practical considerations may be negated by preservation
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techniques such as EVNP, where the organ transplant is treated in isolation Ex vivo .
An acceptable alternate strategy may be to administer preconditioning agents to organ
transplant recipients. This would negate those issues associated with donor pre-
treatment. Moreover, there may be additional benefits to be derived from systemic
treatment; for example, the immune responses within the recipient to the transplanted
organ may be modified, with potential effects on both acute and chronic allograft
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rejection. Recipient preconditioning, although not extensively studied in the literature,
• 171
has been shown to be effective in animal models of cardiac and renal
transplantation179. The over-expression of heme oxygenase-1 (HO-1) has been
reported to confer therapeutic benefits in animal models of IRI and transplantation.
One study in transgenic mice demonstrated improved allograft survival rates in
recipient mice that systemically over-expressed HO-1 when compared with normal
mice that received a graft from a donor manipulated to over express HO-1l71. Some of
this additional benefit may relate to upregulation of HO-1 in the recipient animal's
circulating leukocytes, which subsequently infiltrate the graft and consequently target
therapeutic molecules directly to the site of tissue injury. Clearly, it is essential to
understand whether donor or recipient treatment is the most effective way to employ a
preconditioning strategy.
The endothelium and microvascular dysfunction following IRI
Preservation of an intact renal microvasculature during IRI is emerging as a key
1 88
strategy in prevention of transplant associated injury . IRI causes profound
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disruption to the microvasculature, resulting in microvascular leak and the "no
reflow" phenomenon in which downstream tissue perfusion remains impaired despite
reconnection of the blood supply, due to physical obstruction of the lumina of small
vessels by thrombus, cell debris, leukocytes or by diminished vasodilatation36. The
endothelium is more than a physical barrier between the vascular system and
interstitium. It forms a dynamic interface regulating haemodynamic, inflammatory
and anti-thrombogenic processes. IRI results in endothelial dysfunction by inhibiting
the capacity of the endothelium to regulate these processes. The endothelium
elaborates a variety of substances to maintain vascular homeostasis. Endothelial cells
produce nitric oxide via endothelial nitric oxide synthase. Nitric oxide promotes
vasodilatation and prevents the upregulation of endothelin-1, a potent vasoconstrictor
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induced in ischaemic conditions124. NO also prevents leukocyte adherence to the
endothelium that can further compromise blood flow189. Nitric oxide produced by
endothelial cells inhibits platelet aggregation and cytokine induced expression of
tissue factor190. In addition, hypoxia also reduces the expression of the anticoagulant
thrombomodulin by endothelial cells191 and promotes the expression of a direct
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activator of Factor X . A damaged endothelium, subjected to hypoxic conditions,
therefore promotes thrombosis, which further impairs the blood supply to the distal
tissues. Loss ofNO production leads to an increase in the levels of the vasoconstrictor
endothelin-1 and also diminishes the capacity of the microvasculature for
vasodilatation by NO-mediated mechanisms. These changes predispose the graft to
further ischaemic damage and contribute to the "no-reflow" phenomenon. In addition,
IRI increases vascular permeability by disrupting the physical integrity of the renal
vascular endothelium193' 194. Studies using cultured endothelial cells exposed to
hypoxia have demonstrated an increase in cell permeability secondary to lower levels
of cAMP27'192. Further evidence of increased microvascular permeability is observed
in mice subjected to prolonged hypoxia, with pulmonary oedema and albumin leakage
into multiple organ systems195' 196. In addition, T cells may enhance vascular
permeability in ischaemic renal failure197. The hypothesis that endothelial cell
dysfunction may mediate the haemodynamic consequences associated with IRI is
further supported by a study that showed that renal function was improved in a rat
model of renal IRI by the transfer of viable endothelial cells. Brodsky et al198 used
minimally invasive intravital microscopy to provide direct evidence of the "no reflow"
phenomenon within the peri-tubular capillary network of rats subjected to renal IRI
which was attributable, in part, to endothelial injury. Implantation of endothelial cells,
or surrogate cells expressing nitric oxide synthase resulted in dramatic functional
protection of ischaemic kidneys. The authors conclude that endothelial cell
dysfunction is the primary cause of the "no-reflow" phenomenon.
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Recent advancements in imaging technology have enabled direct visualisation and
analysis of the microcirculation in the immediate aftermath of IRI. Using a rat model
of kidney transplantation Holzen et al199 showed that donor preconditioning with the
HO-1 inducer hemin led to significantly lower serum creatinine and less histological
damage compared with control animals. In vivo microscopy of the renal surface one
hour following reperfusion showed significant enlargement in the vascular diameter
and an increase in the capillary flow in the hemin treated animals. This may relate to
the vasodilatory effects of CO. Andonian et al200 analysed the microcirculation in a
murine model of renal IRI in real time by using targeted microbubbles. These authors
determined that blood flow to the kidney decreased from 554m/s to 182m/s following
simulated renal IRI. The corticomedullary junction, which had the highest rate of
blood flow in animals not subjected to IRI, was the site of the greatest upregulation of
P-selectin following IRI (41% increase compared to increases of 25% in the cortex
and 14% in the medulla). P-selectin is an adhesion molecule that is expressed on
endothelial cells and activated platelets and is an established marker of inflammation
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and ischaemic injury ' , moreover P-selectin facilitates the binding of injurious
leukocytes to the endothelial surface. Administration of anti-P selectin monoclonal
antibody has been shown to attenuate IRI202. The authors conclude that the
corticomedullary junction sustains the highest degree of nephron and microvascular
damage and is most susceptible to ischaemic injury. Such findings correlate with the
model of native kidney IRI used in this thesis, in which the corticomedullary junction
sustains the greatest degree of acute tubular necrosis50 and is the site of greatest
platelet deposition67.
Evidence of a direct link between endothelial dysfunction and adverse clinical
outcomes following renal transplantation in human patients is difficult to obtain.
Schmitz et al66 used non-invasive orthogonal polarization spectral (OPS) imaging to
visualize and quantify cortical kidney microcirculation in 13 combined
kidney/pancreas recipients. Upon reintroduction of the blood supply, a heterogeneous
pattern of perfusion was observed. There was oscillating flow and scattered
microvascular thrombosis of peritubular capillaries, resembling 'no reflow'.
Volumetric capillary blood flow showed a significant positive correlation with the
measured decrease in creatinine between days 1 and 3, linking early microvascular
changes with clinical parameters. The authors conclude that such a technique may
have a future role in predicting early ischaemia reperfusion injury induced graft
dysfunction. In conjunction with the work of Ojo et al23, which linked the severity of
initial IRI with DGF and consequent impaired survival of renal allografts at 5 years,
this suggests that early endothelial dysfunction may play a role in chronic graft loss.
The study of the endothelium in transplanted organs of living transplant patients by
invasive procedures such as multiple renal biopsies is difficult to justify for purely
research purposes. Indirect, non-invasive techniques such as high-resolution brachial
artery ultrasound have been reported to be efficient measures of endothelial
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dysfunction . However, such analyses may be complicated by the fact that
endothelial dysfunction is known to be more commonplace in patients with ESRF
undergoing haemodialysis; such patients are also subject to increased cardiovascular
morbidity and mortality2 4' 05. Moreover, a functioning renal transplant corrects
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metabolic abnormalities and normalises endothelial dysfunction ' . The analysis of
circulating endothelial cells (CEC's) may provide indirect evidence of an association
between microvascular dysfunction and graft injury in transplant recipients. Such
cells become detached from the basement membrane as a consequence of an injurious
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process. Work by Woywodt et al ' measured the numbers of CEC's in the blood
of 129 renal transplant recipients who underwent percutaneous graft biopsy at 1 to
245 months (mean 37 months) following transplantation. The authors reported higher
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levels of CEC's in transplant recipient patients than controls regardless of their biopsy
findings. On biopsy, seven patients had acute vascular rejection, 15 patients had acute
tubulointerstitial rejection and 93 patients had no rejection. Patients with acute
vascular rejection had the highest cell numbers when compared with all other patients.
Mohammed et al210 have also shown a correlation between CEC number and allograft
rejection. These authors conclude that circulating endothelial cells may be a novel
marker of endothelial injury and endothelial dysfunction. The correlation between
rejection episodes and CEC number also suggests an association between endothelial
injury or dysfunction, and adverse outcome following renal transplantation.
Macrophages
Tissue resident macrophages (derived from the Greek macros: large and phagein: eat)
are leucocytes of myeloid lineage. Macrophages are key players in both the innate and
adaptive arms of the immune system. They are derived from circulating monocytes
that exit the circulation via the process of extravasation to become macrophages when
they enter the tissue spaces. This process may occur in response to cytokines released
as part of the inflammatory process by pathogens, dying cells or other macrophages.
In addition to macrophages that are "recruited" from the circulation, tissue resident
macrophages are also found in a number of organ systems under normal
circumstances. Examples include macrophages situated in the liver (Kupffer cells),
brain (microglial cells), bone (osteoclasts) and lungs (alveolar macrophages).
Macrophages are capable of a diverse and complex range of functions211. A
macrophage's phenotype depends upon on its activation status, which is influenced by
a variety of factors including the milieu in which the cells reside and their interactions
212 913with other cell types ' . As a consequence, macrophages may be influenced to
behave in a "pro-inflammatory" or "pro-repair" fashion in differing situations. These
states have traditionally been termed "classically activated" (Ml) and "alternatively
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activated" (M2). Microbial products and cytokines such as IFNy induce macrophages
to adopt an Ml phenotype. Ml macrophages are considered to be "pro-inflammatory"
and are microbicidal through their production of ROS, NO and lysosomal enzymes.
They also produce chemokines and interleukins such as IL-1, IL-12 and IL-23, which
participate in the inflammatory cascade. M2 macrophages by contrast play important
roles in tissue repair, the defence against helminthic parasites and in the resolution of
inflammation. M2 macrophages are induced by cytokines, helminths and interleukins
IL-13 and IL-4. Alternatively activated macrophages elaborate IL-10 and TGF-|3 that
dampen down inflammatory responses, they also produce Arginase, proline and
polyaminases that are involved in wound repair and fibrosis. The separation of
macrophage phenotypes into "pro-inflammatory" and "pro-repair" groupings is
somewhat of an over simplification. It has become increasingly apparent in recent
years that no clear binary distinction exists between Ml and M2 states, rather, there is
a continuum between the two extremes214.
Therapeutic potential of macrophages
It is apparent that macrophages may function in a deleterious or beneficial manner
depending on their microenvironment and the various factors to which they are
exposed. Interest has focussed upon the potential to manipulate macrophage
phenotype toward the "anti-inflammatory" end of the spectrum in an attempt to
modify the outcome in a variety of disease processes in animal models. Macrophages
obtained from experimental animals may be virally transduced, stimulated by
cytokines or subjected to drug treatment to alter their phenotype ex-vivo prior to re-
injection to the animal model as a form of "cell based therapy". In a study using a rat
model of nephrotoxic nephritis, alveolar macrophages were transfected with
adenovirus to induce the expression of the anti-inflammatory cytokine IL-4 prior to
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re-injection into the renal artery 21\ The transformed macrophages localised to
glomeruli and were shown to express IL-4 in-vivo. Treated animals were found to
have reduced levels of albuminuria. Histological markers of glomerular inflammation
and macrophage infiltration were also diminished. Interestingly, a protective effect
was also demonstrated in the contra-lateral, non-injected kidney. This suggests that
such treatments may have effects beyond the mere physical association of altered
macrophages with the structures intended for protection. Potential explanations may
include a more generalised alteration of inflammatory responses at the systemic level
by the modified macrophages. The practicality of translating such techniques into
clinical therapies remains unclear, however, it raises pertinent questions as to the most
effective way of delivering therapeutic benefits from preconditioning strategies that
might depend in part upon macrophage phenotype, and is especially relevant in the
context of organ transplantation. Organ donor treatment may alter the phenotype of
macrophages resident in the transplanted organ, such that they are present at the time
when IRI occurs. They are therefore capable of providing protective benefits in the
immediate aftermath of IRI at which time tissues are most vulnerable to injury.
Treatment of the organ recipient, however, might favourably manipulate systemic
inflammatory responses following organ transplantation. Furthermore, recipient
treatment may affect circulating monocytes within the recipient and thereby facilitate
greater recruitment of altered, therapeutic macrophages from the circulation to the site
of injury. In the context of transplantation, where there is inherent physical
disassociation of organs from donor to recipient, it will be important to accurately
determine which cells are important in affording any protection against injury.
Determining whether HO-1-positive macrophages have a protective role in the
context of organ transplantation is of interest not only on a scientific basis, but may
also have implications for how preconditioning treatments may be employed
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clinically and is of particular relevance given the practical concerns surrounding
organ donor treatment discussed earlier.
The role of macrophages within IRI and transplant systems
Evidence suggests that macrophages play a key role in propagating injury within
• *216217 218animal models of hepatic ' and renal IRI . It has also been demonstrated that
macrophages cause destruction of the renal microvasculature in murine kidney
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transplantation . Several potential mechanisms may be responsible for these effects.
During the relative hypoxia of ischaemia reperfusion injury, macrophages generate
reactive oxygen species that cause direct injury to the transplanted organ, or may
"activate" the endothelium by inducing the upregulation of cellular adhesion
molecules such as ICAM-1 and VCAM-146'216'217. This activation of the endothelium
primes the transplanted organ for direct injury by neutrophils during the subsequent
reperfusion phase of the injury220.
Effect of HO-1 induction upon macrophage phenotype in IRI
Manipulation of macrophage phenotype may therefore offer potential to ameliorate
IRI and emerging evidence suggests that HO-1 induction may play a key role in this.
Induction of HO-1 protein within bone marrow derived macrophages (BMDM) has
67been shown to confer an anti-inflammatory phenotype. Ferenbach et al reported
reduced production of TNFa and nitric oxide combined with increased levels of IL-10
and increased phagocytosis of apoptotic cells in BMDMs that were virally transduced
to overexpress HO-1 prior to stimulation with IFNy and LPS. Such work echoes the
findings of Otterbein et al who demonstrated that the carbon monoxide generated by
the activity of heme oxygenase -1 may have anti-inflammatory effects upon
macrophages221. These authors demonstrated both in vivo and in vitro that carbon
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monoxide at low concentrations inhibited the expression of the LPS induced pro¬
inflammatory cytokines tumor necrosis factor-a, interleukin-ip and macrophage
inflammatory protein-1 (3. CO also increased the expression of the anti-inflammatory
cytokine interleukin-10. Another study demonstrated that inhibition of HO-1 during
culture of BMDMs resulted in adoption of a pro-inflammatory Ly6c+, CD 11c-,
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F4/80- phenotype . It should be noted that, given their inherent complexity and
capacity to be influenced by a range of stimuli, it might be difficult to extrapolate
from in vitro experiments how a macrophage may function within the ever-changing
environment of an in vivo system. More compelling evidence as to the importance of
HO-1 positive macrophages in IRI comes from studies in which such cells are added
or depleted within in vivo models. Kupffer cells have been reported to be the major
source of hepatic HO-1 expression under normal circumstances222. Targeted deletion
of these cells in rat models of hepatic IRI resulted in a reduction of hepatic HO-1
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expression and worsening structural and functional injury ' . Such work implies
that a basal level of HO-1 expression may be important in maintaining tissue
homeostasis following ischaemic injury. Conversely, addition of HO-1 macrophages
may be protective in IRI. Adoptive transfer of BMDMs that were adenovirally
transduced to over express HO-1 has been shown to improve outcome in murine
models of renal67' 224 and hepatic ischaemia reperfusion injury225. Interestingly, the
HO-1 positive macrophages in these studies demonstrated a particular capacity to
"home" to the site of maximal injury. Similar observations were made by Araujo et
al171 in a model of cardiac allograft transplantation which used transgenic mice that
over-express HO-1. These authors commented that the capacity for these cells to
effectively target and infiltrate the site of injury might be especially beneficial. It is
apparent that macrophage phenotype may have important effects within IRI and
transplantation systems. Findings such as those mentioned above raise important
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questions as to how HA treatment might influence macrophage behaviour should this
drug prove to be beneficial in IRI.
Aims
The aims of this thesis are to investigate the capacity for HA treatment to ameliorate
simulated IRI within both in vitro and in vivo settings. Throughout this work, I shall
focus upon changes in the physical integrity of the endothelium, given its key role in
influencing the outcome following IRI. During my in vitro experiments I shall
develop and characterise a model to simulate the oxygen and carbon dioxide tensions
encountered during in vivo IRI. I will investigate whether pre-treatment with HA
protects cells of a murine cardiac endothelial cell line within this model, and seek to
establish whether any such protective effects are due to HO-1 expression by the use of
specific inhibitor substances. In my in vivo experiments I will evaluate the capacity of
HA administration to induce HO-1 within murine organs, and will determine in which
cells and tissues this expression is maximal. In further in vivo work, I shall assess
whether HA treatment is capable of protecting renal structure and function in a
murine model of warm renal ischaemia reperfusion injury. In the final phase of my
experiments, I will assess the capacity for HA pre-treatment to protect renal structure
in a murine model of renal isograft transplantation. A key focus in these transplant
experiments will be to compare and contrast the effects of HA treatment upon donor
and recipient animals. At each stage of the work I shall attempt to identify the
mechanisms that might underpin any protective benefit observed. I will assess
structural changes within the endothelium within these in vivo models through the use
of immunohistochemical techniques and will quantify changes in the populations of a
variety of cell types within pre and post-operative kidneys. I will outline future
experiments that would be prescient in order to clarify which mechanisms that might
be responsible for the observations that I make.
33
Chapter 1: In vitro up-regulation
of HO-1 and modification of cell
injury in a model of IRI
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Aims and objectives
The aims of this phase of experimental work were to establish whether HA treatment
has the capacity to induce HO-1 within a murine cardiac endothelial cell line (MCEC-
1). Preliminary experiments also involved developing a methodology to quantify the
numbers of Hoescht counterstained cells in 12 well plates. This would enable the
analysis of subsequent in vitro experiments. In subsequent experiments an in vitro
model of ischaemia reperfusion injury (IRI) was established and the effects of HA
treatment upon MCEC-1 cells within this model were investigated.
The aims of this chapter are:
1. Establish the capacity ofHA to upregulate HO-1 in MCEC-1 cells.
2. Validate a method for quantifying "viable" Hoescht counterstained MCEC-1
cells.
3. Develop an in vitro model to simulate during IRI
4. Study the effects ofHA pre-treatment of MCEC-1 cells within this system.
Materials and methods:
Chapter 1 Cell Culture and induction of HO-1 in MCEC-1 cells
MCEC -1 cells were cultured on gelatin coated T75 flasks (1% gelatin) in full MCEC-
1 media - Dulbecco's Modified eagle's Medium (DMEM) and 10% Fetal calf serum
(FCS) (GIBCO BRL) with penicillin lOOU/ml, streptomycin lOOmg/ml L-Glutamine
2mM (GIBCO BRL) and endothelial cell growth factor (ECGF 30 pl/ml, Sigma).
MCEC-1 cells were cultured at 33°C and maintained in culture by passaging when the
monolayer was 70-80% confluent. The MCEC-1 cells adopted a "cobble stone"
appearance when confluent (Fig 1.1). Passages 13-15 were used for all experiments.
MCEC-1 cells were plated down in gelatin coated 6 well plates with 250,000 cells per
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well. Medium was refreshed after 3 hours and the cells were kept at 37°C overnight.
The following day the medium was exchanged for medium containing a range of
increasing concentrations of HA solution made up in full media. 0, 1, 10, 25, 50 and
lOOpM HA were selected. The cell plates were shielded from natural light by tin foil
due to the photo instability ofHA and returned to the 37°C incubator for 6 hours. The
medium was then removed, the wells were washed with PBS and the plates were
stored at -20°C until required for protein analysis by western blotting.
Western Blotting of HO-1 protein
Tissue samples were prepared by homogenization in buffer (50mM Tris, 20mM
NaCL, lOmM KCL, 0.1 mM dithiothreitol, ImM EDTA, 1% SDS, pH 7.4)
supplemented with commercially available anti-protease tablets (Amersham, UK) and
subjected to three cycles of freeze thawing. Specimens were centrifuged at 10,000g
for 10 minutes. Protein concentrations were measured on the liquid phase by the Bio-
Rad protein assay reagent (Bio-Rad Laboratories, Hercules, CA). 20 qg of protein
was mixed with equal volumes of 2x laemmli buffer (4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, 0.004% bromphenol blue and 0.125 M Tris HC1) prior to heating to
95°C for 5 minutes. Western Blotting was then performed in the following manner.
Protein samples were loaded onto 4 to 12.5% SDS-PAGE gels, separated by
electrophoresis and transferred electrophoretically onto Hybond-P membranes
(Amersham, Arlington Heights, IL). The membranes were blocked with 5% dried
milk in PBS for 30 minutes prior to incubation overnight at 4°C with polyclonal
rabbit anti-rat HO-1 antibody (1:5000 dilution; Stressgen Biotechnologies, Vancouver,
Canada). This antibody is specific for the HO-1 isoform and does not cross react with
either HO-2 or HO-3. After washing in TBS+0.1%Tween the blots were incubated
with secondary antibody (HRP conjugated goat anti rabbit, Sigma) for lh at room
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temperature, followed by further washes in TBS+Tween. Membranes were treated
with the ECL Plus chemiluminescence system (Amersham biosciences) and exposed
to blank radiographic film (Kodak). Films were developed using an Amersham
Hyperprocessor automated developer. Protein loading was confirmed by reprobing the
membranes with anti (3-actin antibody (Sigma).
Results
Analysis by western blotting showed a dose response type relationship between the
concentrations of HA administered and HO-1 induction. Maximal induction of HO-1
was achieved at 25pM HA. At higher concentrations HA appeared to be toxic to
MCEC-ls. Light microscope images of the cells at these concentrations showed
features of cell lysis with large clumps of cell debris and non-adherent cells visible in
the wells, which implied a toxic effect. This cell death may explain the reduction in
HO-1 expression observed on western blotting from cells treated with higher
concentrations of HA (Fig 1.2). The MCEC-1 cell line demonstrated a degree of
constitutive HO-1 expression, as evidenced by a faintly positive band at 32kDa in the
lysates from cells treated with OpM HA. Such findings might be anticipated as a
consequence of the minor degrees of cellular stress inevitably encountered during
culture conditions. A concentration of 1 OpM of HA was selected for use in future in
vitro experimentation as it achieves sufficient HO-1 induction without apparent
adverse toxic effects.
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Fig 1.1. Light microscope images of MCEC-1 cells. Cells were maintained in




Fig 1.2 HO-1 induction in cultured MCEC-1 cells. Maximal induction is
achieved at a dose of 25uM. Doses above this appeared to be toxic to the
cells.
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Quantification of viable MCEC-1 cells
In order to quantify the results from subsequent simulated IRI experiments, it was first
necessary to develop an accurate method for counting the viable cells remaining on a
culture plate following exposure to an injurious stimulus. In order to achieve this, the
response of MCEC-1 cells to increasing concentrations of a known toxic agent were
assessed. Puromycin was selected for this purpose. Puromycin is an aminonucleoside
antibiotic utilised in cell biology as a selective agent that inhibits protein translation
within prokaryotic and eukaryotic cells. Any quantification method based upon
manual counting must be robust enough to accommodate a tendency for cell death to
occur in an uneven distribution pattern in cell culture.
Method
MCEC-1 cells were plated onto gelatin coated 12 well plates at a concentration of
100,000 cells per well. Cells were left to adhere overnight at 33°C. The following day
the medium was exchanged for standard medium containing 0, 0.25, 0.5, 0.75, 1.5 or
10 mcg/ml of Puromycin. Plates were maintained at 37°C for 24 hours and fixed with
200p,l of 39% formaldehyde with methanol at 4°C for 24 hours. The wells were then
washed twice with PBS and treated with 500pL of a solution containing 1 mcg/ml of
Hoescht 33342 for 20 minutes. During this time plates were protected from natural
light and kept at 4°C. Wells were then washed twice with PBS and coated with 75pL
of a solution containing glycerol and a light quenching agent prior to image capture
on an inverted microscope.
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Image capture
Wells were photographed at x200 magnification on an inverted microscope. All the
images were stored under coded numbers and quantification of the stored
photographic images was undertaken at a later date to ensure that the analysis was
performed in a blinded fashion. Wells were roughly subdivided into 10 positional
"zones" (Fig 1.3). A single image was taken at random from each of these areas in
each well. This technique was employed to provide a sufficient quantity of images,
with an even representation of the well that would be consistent between runs of the
experiment.
Results
Exposure to increasing concentrations of Puromycin resulted in a significant reduction
in the numbers of "viable" MCEC-1 cells remaining within wells on completion of
the experiment (Fig 1.4, Mean no. of viable cells/hpf: 20.7 ± 1.9 vs. 11.8 ± 1.6 vs. 7.3
± 1.7 vs. 4.1 ± 0.8 vs. 0.8 ± 0.2 vs. 0.1 ± 0.06 vs. 1.4 ± 0.3; 0 vs. 0.25 vs. 0.5 vs. 0.75
vs. 1 vs. 5 vs. 10 mcg/ml puromycin; p<0.05, n=3). Moreover, the graph follows a
smooth "dose response" type pattern, as might be anticipated from such an
experiment. These findings suggest that this is a robust method for assessing viable
MCEC-1 numbers.
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Fig. 1.3 Schematic diagram illustrating the 10 positional "zones" from which
photographic images were taken for quantification.
Puromycin Dose mcg/ml
n=3 *p<0.05
Fig 1.4. Dose response curve demonstrating a significant reduction in the
numbers of viable MCEC-1 cells with increasing Puromycin dose (n=3
p<0.05)
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In vitro model to simulate the conditions of IRI
Early work focussed on attempting to devise an in vitro experimental model to
simulate the changes in gaseous tensions that are encountered within tissues during
periods of ischaemia and subsequent reperfusion.
Time course exposure to simulated IRI
MCEC -1 cells were cultured as described previously. 100,000 cells were plated into
12 well plates that had been pre-coated with 1% gelatin and contained DMEM with
10% FCS. The cells were left to adhere overnight at 37°C. One plate was then
returned to the 21% O2, 5% CO2 incubator as a "normoxic" control. The remaining
plates were placed immediately in a Biospherix chamber that was calibrated to
gaseous tensions of 0.5% O2 and 11.5% CO2 (Biosperix Ltd, New York, USA). These
conditions are referred to as being those of "hypoxia and hypercarbia" (HCR). Upon
placing the plates within the Biospherix chamber, the wells were immediately
refreshed with medium that had been "degassed" for 20 minutes under conditions of
HCR (0.5% O2 and 11.5% CO2). Experimental groups included exposure to HCR for
periods of 8, 16 and 24 hours. In early experiments blood gas analysis was performed
on the medium at this point to confirm the oxygen and carbon dioxide concentrations.
Upon completion of the timed exposure to HCR, the medium in all the plates was
replaced with 1 ml DMEM with 10% FCS that had been maintained in room air
gaseous tensions. All the plates were then returned to the 21% O2, 5% CO2 incubator
for a further 24 hours. This was intended to simulate the reperfusion phase of IRI in
which exposure to increased Oxygen tensions leads to production of harmful reactive
Oxygen species. At the end of the experiment the cells were fixed with formaldehyde
(4% final concentration) and remaining adherent cells were stained with Hoechst
33342 (Schematic of experimental procedure in Fig 1.5). 10 high-power field
photographs per well were taken as previously described under inverted fluorescent
42
microscopy (X 200 objective). Results were expressed as counts of viable cells per
high-powered field.
Results
This experiment confirmed that MCEC-1 cells were significantly injured when
subjected to conditions ofHCR as indicated by a reduction in the numbers of viable
MCEC-1 cells and the presence of apoptotic bodies and cell debris in images taken
from wells exposed to (HCR) (Fig 1.6). It was noted that there was a consistent
tendency for the cell death to occur in an uneven fashion from the top right of the well
(zone 3) progressively toward the centre (zones 5-6) and then toward the bottom left
(zones 5,6,8,9). The reasons for this effect remained unexplained. This pattern
confirmed the necessity of capturing images from defined areas as indicated in earlier
methods. A significant reduction in the numbers of viable MCEC-1 cells per high-
powered field was seen upon exposure to HCR for periods of 16 hours, compared to
those cells maintained in normal oxygen tensions (31.5± 1.0 vs. 17.33±2.7; Normoxia
vs. 16 hours HCR; n=3, p<0.05) and 24 hours (31.5±1.0 vs. 1.6 ± 0.78; Normoxia vs.
24 hours HCR; n=3, p<0.05) but not at the 8-hour time-point (31.5 ± 1.0 vs. 25.6
±7.3; Normoxia vs. 8 hours HCR; n=3, p=0.7) (Fig 1.7). A 24-hour time point was
selected for the purposes of future experimentation using this model. This time point
selected for use in future experiments as it was practical in terms of organisation of




6 hours DMEM 10%FCS
6 hours pre-treatment lOpM HA
Stage 1: 100,000 MCEC-1 cells were added to 12 well plates. After being left to
adhere for 6 hours, half the wells were treated with 10pM HA. Medium on the control
wells was refreshed with DMEM containing 10% FCS.
24 Hours 24 Hours
10% FCS Media
21% 02 10% FCS Media
0.5% 02, 11.5%C02
Stage 2: Plates were placed either in a hypoxic chamber equilibrated to 0.5% 02
and 11.5% C02 (HCR) or within an incubator with containing normal Oxygen and
Carbon Dioxide concentrations (Normoxia). After 24 hours, all the plates were
returned to normoxic conditions and the medium in all wells was refreshed. After a
further 24 hours the experiment was concluded.
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Stained with Hoescht 33342
Counts of viable cells per lOx random
high powered fields
Supernatants + adherent cells
Flow cytometry with Propidium Iodide
Stage 3: Cells were fixed with formaldehyde (4% final concentration) at the
conclusion of the experiment. Readouts of viable Hoescht stained cells adherent to
the base of the well were obtained. In subsequent experiments the contents of the




Fig 1.6 : Cells maintained in Normoxia and stained with Hoescht compared
with those exposed to 24 hours HCR. HCR exposed cells are markedly fewer





Fig 1.7 : Time- course experiment demonstrating significant reductions in the
number of viable MCEC-1's following exposure to 16 and 24 hours HCR (n=3,
p<0.05)
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The effect of Heme arginate pre-treatment on MCEC-1 cell number
following exposure to simulated IRI
Method
MCEC-1 cells were cultured as described previously. 100,000 cells were plated into
12 well plates in DMEM with 10% FCS. The wells were pre-coated with 1% gelatin.
Cells were left to adhere overnight at 37°C. Half the wells were then treated for 6
hours with 2 mis of lOpM Heme arginate (Normosang; Leiras Oy Pharmaceuticals,
Finland) in DMEM with 10% FCS. Control wells received 2mls of full media. After 6
hours the medium on all the plates was refreshed with DMEM with 10% FCS. Half
the plates were then returned to the 21% O2, 5% CO2 incubator. The other plates were
refreshed with medium that had been degassed for 20 minutes in hypoxic conditions
(0.5% O2, 5% CO2). These plates were then placed immediately in conditions of
hypoxia and hypercarbia for 24 hours (0.5% O2 11.5% CO2, Biospherix chamber,
Biosperix Ltd, New York, USA). The medium on all wells was then replaced with 1
ml DMEM with 10% FCS and all plates were returned to the 21% O2, 5%CC>2
incubator for a further 24 hours. Cells fixed with formaldehyde at the end of the
experiment (4% final concentration) and the remaining adherent cells were stained
with Hoechst 33342. 10 high-power field photographs per well were taken under
inverted fluorescent microscopy (X 200 objective). Results are expressed as counts of
viable cells per high-powered field. In subsequent experiments, performed in a similar
manner, cells remained unfixed. In these experiments the supernatants were harvested
and combined with adherent cells that had been gently removed from the base of the
well after trypsinisation (100pl trypsin for 10 seconds followed by blocking with
DMEM with 10% FCS) and gentle agitation with a pastette. The cells were stained
with propidium iodide (Sigma) and analysed by flow cytometry. Results were
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expressed as % propidium iodide-positive cells. Experiments were subsequently
repeated in a similar fashion with the inclusion of two control groups pre-treated with
full medium containing lOuM HA and 50pM of Zinc protoporphyrin (one maintained
in normoxia, the other in conditions of HCR). Upon completion of the experiment
these plates were stained with Hoescht 33342 and then photographed under the
inverted microscope and counted as described previously.
Results
Counts of viable cells per random high-powered field were reduced in untreated cells
following exposure to HCR when compared with untreated cells maintained at normal
oxygen tensions. Cells pre-treated with 1 O^iM HA were significantly protected against
conditions of HCR (Fig 1.8; 30.9 ±1.7 vs. 7.0 ± 3.2 vs. 20.0 ±3.1; Normoxia vs. HCR
vs. HA+HCR; n=4 p<0.05). In subsequent experiments, a reduction in positive PI
staining was observed following treatment with HA prior to HCR when compared
with controls (Fig 1.9; % positive PI staining; 6.8% vs. 78.7% vs. 43.4%; Normoxia
vs. HCR vs. HCR+HA; representative figures from one experiment). In later
experiments that included ZNPPiX treatment groups, the protective effect ofHA pre-
treatment was replicated (Fig 1.10; 32.9 ± 0.7 vs. 1.5 ± 0.7 vs. 20.7 ± 0.5 Normoxia vs.
HCR vs. HA+HCR; n=3, p<0.05). A reduction in cell number was also seen in cells
that were maintained at normal oxygen tensions and received HA and ZNPPiX when
compared to cells that received HA alone (Fig 1.10, 32.6 ± 0.5 vs. 22.4 ± 2.8;
Normoxia + HA vs. Normoxia+HA+ZN; n=3, p<0.05 unpaired t-test). There was also
a clear trend toward abrogation by ZNPPiX of the protective effect of HA in this
experiment although this did not reach statistical significance (17.8 ± 3.2 vs. 8.1 ±














Fig 1.8. Significantly fewer viable MCEC-1 cells remain after 24 hours
exposure to HCR compared with normoxic controls. Cells pre-treated with
10pM HA are significantly protected from this injury (n=4, p<0.05)
X
CD
10' 10' 10' 10* 10"
FL2-H
Fig 1.9 - Normoxia. Cells maintained at normal Oxygen tensions for 24 hours
exhibit similar degrees of positivity for PI. Red line - untreated cells, 6.82% PI
positive: Blue line - cells pre-treated with 10pM HA for 6 hours, 4.93% PI
positive. Representative plot taken from 3 experiments.
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FL2-H
Fig 1.9 - HCR. Cells exposed to conditions of HCR for 24 hours. Red line -
untreated cells, 78.7% PI positive: Blue line - cells pre-treated with 10j.iM HA
for 6 hours, 43.4% PI positive. Representative plot taken from 3 experiments.
u. 35-1
n=3 *p<0.05
Fig 1.10 - Pre-treatment with 10pM of HA significantly protects MCEC-1 cells
exposed to 24 hours HCR (n=3, p<0.05). Cells maintained in normoxia and
treated with HA and Zinc were significantly fewer when compared to those
cells that just received HA treatment (n=3, p<G.05). There was a trend toward
an abrogation of the protective effects of HA in cells that received ZNPPiX, a
specific inhibitor of HO-1 (n=3, p=0.07)
Summary
These data demonstrate that:
1. HA treatment ofMCEC-1 cells induces HO-1.
2. MCEC-1 cells that received pre-treatment with HA were more numerous and
exhibited less cell injury (as measured by PI staining) following simulated IRE
3. Use of a specific inhibitor of HO-1 appeared to abrogate this protection.
Although the differences between the groups fell short of statistical
significance, it does seem to imply that HO-1 activity may be responsible for
the protective effects observed.
Discussion
Primary endothelial cell lines have traditionally proved difficult to isolate, the
techniques required to do so being both time consuming and costly. Such cultures
often yield only small numbers of cells that do not readily withstand the processes of
passaging, frequently becoming senescent at low passage numbers. This has limited
their use in a variety of experimental conditions. The use of immortalized cell lines is
associated with undesirable phenotypic changes such as reduced responsiveness to
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cytokine stimulation and the loss of surface antigens . Furthermore, immortalized
cell lines are unsuitable for the study of endothelial cell proliferation. In these
experiments I used the murine cardiac endothelial cell line (MCEC-1) that was
originally described by Lidington et al228. These authors successfully isolated growth
factor responsive cardiac endothelial cells from a strain of transgenic mice (H-2Kb-
tsA58228). MCEC-1 s are characterised by their capacity to form tubules and by their
expression of CD31, ICAM-2 and endoglin. MCEC-Is also harbour a temperature
sensitive simian virus 40 large Tag gene under H-2K class 1 promotor control, which
ensures that they proliferate rapidly when incubated in permissive conditions (33°C
with IFNy). Proliferation was reduced by 30-fold when the cells were exposed to non-
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permissive conditions (38° without IFNy). This temperature sensitivity makes the
proliferation of the cells easy to regulate under laboratory conditions and enhances the
practicality of the cell line. Lidington et al also demonstrated a capacity for these cells
to express E- and P-selectin, ICAM-1 and VCAM-1 in response to stimulation with
the cytokines TNF a and IL-1 (3. This contrasts with the author's previous experience
with immortalized human endothelial cell lines such as HMEC-1, ECV304 and
EaHy926 which failed to show such a response to cytokine stimulation226. These
characteristics make the MCEC-1 cell line a practical tool to study endothelial cell
function in response to inflammatory stimuli. Indeed the MCEC-ls have been used to
demonstrate that TIMP-3 regulates the release of the soluble ectodomain of VCAM-1
• • 229from cytokine stimulated endothelial cells . Whilst MCEC-1 cells have been shown
to express CD31 by the original authors, this positivity appeared to be lost with
increasing passage numbers. This has been suggested to be due to enzymatic digestion
by trypsin230. This loss ofCD31 expression has raised the question as to whether these
cells can truly be regarded as endothelial cells or whether they de-differentiate from
their original phenotype as they are passaged. Accordingly, only low and similar
passage numbers were used in this series of experiments. The extent to which the
biology of MCEC-ls may mimic responses in renal endothelial cells is also an
important question. Endothelial cells derived from different anatomical locations may
i • 231 •
display differing structural and functional characteristics (reviewed in ). Craig et al
found intrinsic structural differences between endothelial cells derived from
capillaries compared with those from large vessels232. In this paper, only endothelial
cells derived from brain capillaries were shown to possess tight junctions by electron
microscopy, whereas only the endothelial cells derived from large vessels (in this case
the aorta) contained Weibel-Palade bodies. Gumkowski et al233 demonstrated
significant functional heterogeneity between microvascular endothelial cell cultures
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derived from a variety of murine organs including lung, liver, brain, heart, placenta
and kidney. These cell lines differed in their expression of cell surface antigens,
angiotensin-converting enzyme and by differential binding of various plant lectins.
Such differences are likely to reflect the range of functions performed by the
endothelium at each site and are perhaps to be expected. This heterogeneity highlights
the complexity of the vascular bed as a whole and has implications for how relevant
data obtained from a cell line from one organ may be to the behaviour of endothelial
cells within another organ system. There are of course inherent difficulties in
extrapolating findings made in vitro to those that may be made in vivo in any case.
Unfortunately there remains a paucity of commercially available renal endothelial cell
lines at the present time. The notable exception to this is the REC-A4 line that is
derived from renal microvascular endothelium obtained from normal mouse tissues234.
These cells retain morphological and ultrastructural similarities with resting
microvascular endothelial cells. However, the use of REC-A4 cells is currently not
widespread outwith the institution that initially characterised the cell line.
Attempting to accurately model the phenomenon of ischaemia reperfusion injury in
vitro is immensely challenging. IRI is a complex in vivo process that consists of an
ischaemic phase of variable duration, followed by a reperfusion phase that is
associated with the generation of reactive oxygen species and a subsequent cellular
influx. This infiltrate is composed of differing populations of cells that are recruited in
a specific temporal sequence. The present model differs from in vivo IRI several
respects. The real physical structure of the microvasculature is composed of
endothelial cells that form 3 dimensional, branching tubular structures, not a single
cell monolayer as is represented in these experiments. The model does not reproduce
the temperature variations to which organs are exposed prior to transplantation. The
model also does not replicate the effects of turbulent blood flow that are encountered
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in vivo, which may be relevant as sheer stress has been reported to play a role in HO-
1 induction in the endothelium235. In reality transplanted organs are unlikely to be
exposed to such lengthy periods of ischaemia. The 24-hour exposure time point used
in these experiments was selected upon the basis of the level of injury that results, and
the practicality of that time-point for experimental purposes. More limited ischaemic
times may result in a lesser degree of endothelial cell loss and greater degrees of
endothelial cell activation and endothelial dysfunction191' 194. This may have some
bearing upon the nature of the subsequent injury, with effects such as the loss of
barrier function, cellular infiltration, vasoconstriction and thrombosis potentially
playing more important roles than cell loss through necrosis per se. The changes in
oxygen and carbon dioxide concentrations that are used in this model replicate only
one component of the real injury; accordingly, this model does not reflect the entirety
of the processes that occur during IRI in vivo. Such events are almost impossible to
model accurately within the laboratory setting, the number of variables required to do
so would result in highly complex, impractical experiments. The majority of studies
attempting to model IRI in vitro focus upon one component of the injury. Harrison et
al236 demonstrated that heat shock protein 90 binding agents protect a human renal
adenocarcinoma cell line (ACHN) against the oxidative stress induced by exposure to
Hydrogen peroxide (H2O2) mimicking the generation of free radicals encountered
when the oxygen rich blood supply is restored during the reperfusion phase of IRI.
Others have manipulated gaseous tensions to simulate the processes of ischaemia
followed by reperfusion, as I have done. Zenebe et al237 using an air-sealed chamber
infused with either air or Nitrogen, demonstrated that hypoxia followed by re-
oxygenation caused cytochrome c release and oxidative stress in cardiac mitochondria
via a nitric oxide synthase dependent mechanism. Other researchers have replicated
the low temperatures to which organs are exposed during periods of storage prior to
implantation .
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One of my central hypotheses is that endothelial cell damage forms a critical early
event in IRI. Loss of endothelial cells and physical disruption of the microvasculature
are important factors that predispose organs to ongoing downstream ischaemic
damage66. This model, albeit crude, does reproduce the ischaemic conditions
encountered during in vivo IRI and allows us to evaluate how those conditions affect
endothelial cell survival. It also allows us to assess how HA modulates this injury.
The settings for the Biospherix chamber used for these experiments were selected in
accordance with a clinical study that measured the partial pressures of Oxygen and
Carbon Dioxide within clamped ischaemic organs during surgical procedures .
The simulated IRI experiment outlined in this chapter was analysed using two
different readouts. The use of viable cell number counts and Propidium iodide (PI)
provide measures of both cell survival and cell injury respectively. Propidium Iodide
is an intercalating agent that binds to double-stranded DNA, but can only cross the
plasma membrane of non-viable cells. As such, cells that are positive for PI have
compromised membrane integrity. Further sub classification into cells that are
undergoing necrosis and apoptosis is possible by alteration of the settings upon the
flow cytometer, or by the additional use of Annexin V, which binds to the
phosphatidylserine that becomes exposed on the surface of cells undergoing apoptosis.
The results presented here represent merely PI positive cells and as such include both
apoptotic and necrotic cells. It may be of interest to attempt to differentiate between
these modes of cell death given the emerging evidence attesting to the
immunomodulatory effects of apoptotic cells213. It should be noted that each read-out
also analyses a slightly different aspect of the experiment. Only those cells that
remain adherent to the base of each well are visualized and included in the "viable
cell counts", the supernatents that may contain injured endothelial cells that might be
56
dislodged from the monolayer were disregarded. In contrast, the entire contents of the
well were analysed by PI staining in subsequent runs of the experiment. It seems
likely that the contents of the supernatent will largely consist of debris and injured
cells that have become detached from the monolayer. It is therefore doubtful that the
contents of the supernatent will alter counts of viable cells as such. Enzymatic
digestion and well scraping both have the potential to injure cell membranes and
therefore increase positive PI staining, giving an erroneous impression of increased
injury levels. Accordingly, great care was taken when preparing cells for flow
cytometric analysis to ensure that all groups were exposed to short, identical periods
of trypsinisation prior to quenching with medium containing 10% FCS. The use of
two separate readout measures in this system strengthens the evidence for a protective
effect of HA. HA pre-treatment was shown not only to reduce cell injury, but also to
increase the number of remaining viable cells.
In these experiments, Zinc Protoporphyrin (ZZPPiX) was used as a specific inhibitor
of HO-1. This agent is widely employed in the literature on HO-1 in this capacity90'93'
l73. The use ofmetalloporphyrins in the investigation of a physiological role for HO-1
has been criticized due to their capacity to inhibit NOS and sGC activity240"242.
Appleton et al243 have shown, however, that ZNPPiX when administered at a
concentration of 50 pM can inhibit HO activity without significantly inhibiting the
activity of either nitric oxide synthase (NOS) or soluble guanylate cyclase (sGC) and
this dose has been commonly employed in the literature244"246. Within these
experiments there was a significant reduction in the numbers of viable MCEC-1 cells
within control groups that were maintained in normal oxygen tensions and received
both HA and ZNPPiX. It is possible that this may represent a toxicity effect of
ZNPPiX and therefore that the apparent trend toward abrogation of the HA mediated
protection against conditions of 1ICR might be due to toxicity of the inhibitor rather
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than inhibition of the protective effects of HO-1. An alternative explanation might be
that a level of constitutive expression of HO-1 is required to protect these cells against
a variety of stresses that they encounter routinely during cell culture, or to prevent a
degree of apoptosis that these cells might otherwise normally undergo174. Reference to
Fig 1.1 indicates that untreated MCEC-1 cells do express HO-1 when they are
maintained in 12 well plates. Such expression may be necessary for their survival.
Future work to establish the effects of ZNPPiX might include HO-1 activity assays to
verify functional HO-1 induction by HA and functional inhibition by ZNPPiX
administration. Alternatively, short interfering RNA (SiRNA) may be utilised to
specifically "knock out" HO-1 and therefore confirm that the protection seen in this
system relates to an effect of HO-1 activity.
Future work
These data as presented do not explain the mechanisms responsible for the protective
effect of HA administration within this experimental system. Future experimental
work would principally be directed toward definitively clarifying whether enhanced
HO-1 expression was implicated by the use of siRNA to "knock out" the FIO-1 gene
within this cell line prior to HCR. Thereafter it may also be of value to determine
whether one of the individual breakdown products of HO-1 activity provides
endothelial cell protection against HCR in isolation, or whether such protection is
multifactorial. Several previous studies have suggested that one or more of these
947 9 SO
substances may be protective under a variety of experimental conditions " Carbon
monoxide releasing molecules (CORMs) are commercially available, as are both
biliverdin and bilirubin. These substances could be added individually to MCEC-1
mono-cultures immediately prior to HCR to assess their potential protective effects.
Exogenous treatment with iron is unlikely to be rewarding as its therapeutic benefits
may be mediated through its rapid depletion by the post-transcriptional up-regulation
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of ferritin. Ferritin sequesters other Fe2+ ions in the milieu, preventing the generation
of harmful reactive oxygen species (ROS) via the Fenton reaction165'249.
IRI is a highly complex, multifactorial phenomenon In Vivo. However, the basic
experimental model described might be further adapted to evaluate other key aspects
of the process. For example, some authors have shown that HO-1 positive
macrophages may mediate the therapeutic benefits of HA treatment within an in vivo
model of IRI in aged mice50. HA pre-treated mice in this study showed reduced levels
of acute tubular necrosis (ATN) following simulated IRI. It would be interesting to
co-culture HA pre-treated macrophages with either MCEC-1 cells or primary cultures
of renal tubular epithelial cells and expose them to conditions of HCR. HO-1 over-
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expression induces an anti-inflammatory phenotype within macrophages ' ' and
a growing body of evidence suggests that HO-1 positive macrophages may be
protective within in vivo models of IRI50' 22' 224. Direct and indirect in vitro co-
cultures may clarify whether any therapeutic benefits occur as a result of a substance
produced by HO-1 positive macrophages (such as CO) or due to direct cell-to-cell
contact. Such experiments would have to be appropriately designed to address a
number of potential confounding factors. Firstly, an observation from my own
preliminary work was that MCEC-1 cells when plated at higher numbers and
increasing levels of confluence, were more resistant to injury due to HCR. This
finding may make comparison of co-culture groups with control "MCEC-1 only"
groups problematic. The presence of an additional population of cells in the well at
varying ratios to the MCEC-1 cells may physically shield the MCEC-1 monolayer
from exposure to the conditions of HCR. My experience with this model suggested
that MCEC-1 cells were more resistant to injury unless they were abruptly exposed to
the degassed HCR medium. Potentially, a more gradual exposure to conditions of
HCR, might occur should MCEC-ls be physically "shielded" by another cell layer
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layintop of them in co-culture. This might provide the endothelial cells with sufficient
time to upregulate their own cellular defence mechanisms such as HO-1. Co-cultures
may therefore potentially demonstrate protection through a partly physical effect.
Secondly, it is known that hypoxia results in both vascular endothelial cell growth
factor (VEGF) and hypoxia inducible factor (HIF-la) production by macrophages253.
VEGF production might confound observations by increasing MCEC-1 numbers
through proliferation. HO-1 expression has also been shown to be HIF-la
dependant254, which is likely to result in increased HO-1 production within control
groups. I undertook some preliminary direct co-culture experiments with HA treated
and untreated macrophages and MCEC-1 cells under conditions of normoxia and
HCR. In this work the cells were cultured at a ratio of 2 macrophages to 1 MCEC-1
cell. I attempted to analyse the results using the image capture and cell counting
technique described in this chapter, the final readout being mean number of viable
MCEC-1 cells per high-powered field. Staining with Hoescht alone would not
distinguish between the two cell types, as all cells stained with this marker appear
fluorescent under the inverted microscope. Although macrophages and MCEC-1 cells
differ morphologically (MCEC-1 cells are physically larger) a more reliable way of
differentiating between the two cell types was needed. I attempted to label the
macrophages using "cell tracker" dyes, staining the endothelial cells orange and the
MCEC-1 cells green dyes in accordance with a method originally described by
Duffield et al . Unfortunately I found the dyes to be a temperamental and either one
or the other cell line would consistently fail to stain strongly. Even when the cells
were labelled correctly it could be difficult to count viable MCEC-1 cells. The crisp,
intense staining of the cells nucleus with Hoescht makes asesment of the viability of a
cell relatively straightforward. In contrast, the cell tracker dyes provide less distict
staining and less nuclear definition which makes counting and assessing viable cells
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more problematic. In addition, the presence of macrophages within the wells partially
obscured the MCEC-1 monolayer, hampering accurate quanification. I did attempt to
use Hoescht staining alone for quantification in some runs of these experiments, as I
thought distinction between the two cell types on size grounds alone may have been
possible. The results I obtained with this method seemed to suggest that the presence
of either treated or untreated macrophages resulted in a trend toward MCEC-1
preservation. However, it is clearly possible that inadvertent counting of some
macrophages as viable MCEC-1 cells may explain these results. Repition of this
experiment using flow cytometry to sort the cells into macrophages and endothelial
cells groups and assessing PI and annexin V positivity may negate these issues and
provide an accurate assessment of necrotic and apoptotic MCEC-1 cell numbers.
Endothelial cells express ICAM-1 and P-selectin upon exposure to conditions of
hypoxia and re-oxygenation in vitro through upregulation of MAP kinase
signalling256"258. Increased adhesion molecule expression has also been demonstrated
in the microvasculature of human kidney allografts46. This endothelial activation
represents a critical event in IRI and facilitates the infiltration of an injurious
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population of cells including neurophils . The extent to which E-selectin may also
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play a role in renal IRI has been debated ' . Bilirubin and the depletion of free Iron
associated with HO-1 activity have been shown to inhibit the ability of pro¬
inflammatory cytokines such as TNFa and IL-1(3, to induce the expression of the
adhesion molecules E-selectin, P-Selectin, ICAM-1 and VCAM-1 via inhibition of
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NF kappa B" , and carbon monoxide is known to attenuate ICAM -1 expression by
969 ...
inhibiting NFKB . Therefore, in addition to protecting the physical integrity of the
endothelium, HO-1 may reduce endothelial activation and leukocyte induced injury as
a consequence. It would be valuable to assess this in vitro, perhaps by using
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abbreviated exposure to HCR and evaluating the expression of adhesion molecules in
control groups and groups pre-treated with HA.
It might be suggested that the increased cell numbers seen in the HA treated groups in
this experiment are as a result of increased proliferation, rather than protection of
existing cells from the conditions of HCR. The literature is divided as to whether HO-
1 expression or the breakdown products of heme metabolism can stimulate
proliferation. Otterbein et aL showed that CO increased hepatocyte growth factor
expression in hepatic stellate cells, but not in hepatocytes. Increased hepatocyte
proliferation was observed when these two cell types were co-cultured together.
However, CO has also been shown to exhibit anti-proliferative effects in vascular
smooth muscle cells via mechanisms dependent on the activation of sGC and p38
MAPK 264 26\ It is possible that the specific effects of this molecule may vary
between organ systems and cell types. Indeed. Li Volti et al266 suggest that HO-1
regulates the cell cycle in a cell-specific manner. Their data demonstrate that HO-1
increases endothelial cell cycling but decreases smooth muscle cell cycle progression
in vitro. Formal assessment of proliferative activity, for example, by means cell cycle
analysis following PI staining on tlow cytometry would clarify this issue within this
experimental system.
This phase of experimental work demonstrates that HA treatment upregulates HO-1 in
MCEC-1 cells and protects them from conditions of hypoxia and hypercarbia similar
to those encountered in IRI in vivo. Use of the specific inhibitor ZNPPiX suggests
that this protection may be wholly or in part due to an effect ofHO-1 activity.
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Chapter 2: In vivo induction of
HO-1 following HA administration
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Aims and objectives
Results from the previous chapter established that HA treatment induces HO-1
expression within cultured murine cardiac endothelial cells and protects them against
simulated IRI in vitro. The next phase of experimental work investigates the effect of
intravenous HA injection upon HO-1 expression within mice.
The aims of this chapter are:
1. Establish the capacity for HA administration to upregulate HO-1 in vivo
2. Determine the optimum dose for use in future in vivo experiments
3. Clarify whether HA treatment can induce functionally active HO-1
4. Localise HO-1 upregulation to specific cell types within a range of organs
Determining the effect of IV Heme arginate upon HO-1 expression in vivo
Methods
6 week old FVB mice (Harlan, UK) were administered either 200pL of PBS or the
same volume of a solution containing 3, 15 or 30 mg/kg Heme arginate solution via
tail vein injection. 3 mice were tested per group. After 24 hours the mice were
terminated via cervical dislocation in accordance with Home Office guidelines.
Spleen, liver and kidney were retained for further evaluation. HO-1 expression was
localised by immunohistochemistry. Baseline expression of the enzyme was
quantified by western blot analysis. Bioactivity assays were performed to confirm
functional upregulation of the enzyme.
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Immunohistochemistry
Whole kidneys were cut longitudinally and either snap frozen in liquid nitrogen (for
future use in bioactivity assay) or fixed in methyl Carnoy's solution (60% methanol,
30% chloroform and 10% acetic acid). HO-1 expression was assessed following
antigen retrieval in citrate buffer (lOmM sodium citrate, 0.05% Tween. Microwaved
at 800W for 3 x 5 min). Sections were then incubated with rabbit anti mouse
polyclonal antibody (1/500 dilution; 4°C overnight; Stressgen Biotechnologies,
Vancouver, Canada). Primary antibody was incubated at 4°C overnight with
subsequent incubation with mouse-adsorbed biotinylated rabbit anti-rat IgG (1/300
dilution; Vector Laboratories, Peterborough, UK) at room temperature (RT) for 30
minutes. After washing, sections were incubated with Vectastain ABC Elite reagent
(Vector Laboratories, Peterborough, UK) for 30 minutes at RT, prior to further
washing and staining with diaminobenzidine (DAB) (Dako UK, Cambridgeshire, UK).
Counterstaining was performed with haematoxylin prior to dehydration and mounting.
Whole mouse serum was used instead of primary antibody in sections included as
negative controls.
HO-1 bioactivity assay
HO-1 bioactivity assays were performed to confirm the presence of a functionally
active enzyme. Tissue samples were prepared and protein concentrations assayed as
described in chapter 1. As a source of biliverdin reductase, human liver cytosol was
obtained by homogenising samples of liver in buffer H (0.1M sodium citrate, 10%
glycerol, pH 5), and collecting the supernatant following centrifugation at 105,000g
for 30 minutes. A 400pL reaction mixture was then created, containing: 500pg of
tissue protein; 1.5mg liver cytosol; 0.8mM NADPH; 2mM glucose; 6 mM phosphate;
0.2 units glucose 6 phosphate dehydrogenase; and 20pg hemin. The volume was
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made up to 400p,L in buffer Hs. The mixture was then incubated in the dark at 37°C
for one hour. The reaction was terminated by adding 400pL of chloroform and
vortexing for 20 seconds, followed by centrifugation at 10,000g for one minute. The
chloroform phase was then collected, and the bilirubin content measured by
spectrophotometry, using the difference in absorption at 464 and 530nm, and an
absorption coefficient of 40mM"lcm~l. Results were expressed as pg of bilirubin
formed per mg protein per hour.
Dual immunofluorescence CD68 and HO-1
Frozen tissue was embedded in OCT mounting media and 5 micron sections cut, air
dried and fixed in ice-cold acetone. After protein blockade for 30 minutes (Spring
Bioscience, CA) primary antibodies (polyclonal Rabbit anti HO-1, 1:300 dilution, rat
anti-mouse CD68, 1:100 dilution) were added simultaneously and incubated for lh at
room temperature. Following washing in PBS, secondary antibodies (Alexa-488
conjugated Goat anti-Rat Ig 1:250 and Alexa-594 Donkey anti-rabbit Ig 1:500, both
Invitrogen) were added simultaneously for 1 hour. Slides were coverslipped with
Vectashield containing DAPI (Vector Labs) prior to microscopy and image
acquisition. Images analysis was performed using Photoshop CS3.
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Results
I.V. administration of Heme arginate upregulates functional HO-1 protein
in murine renal tissue 24 hours post injection
A dose of 30mg/kg i.v. HA was found to reliably upregulate HO-1 protein
predominantly in the tubules of the renal cortex rather than those of the medulla (Fig.
2.1). Western blotting performed to quantify this staining confirmed induction of HO-
1 in renal tissue in a dose response pattern to a maximum at 30mg/kg (Fig. 2.2).
Activity assays verified that HA treatment resulted in a significant induction of
functional HO-1 protein, again following a dose response type pattern to maximum
functional activity at a dose of 30mg/kg HA (Fig. 2.3. 66.7±13.3 vs. 480±100.7
bilirubin pmols/mg/hr; 3mg/kg vs 30mg/kg HA; n=3, p<0.05). Of note, a consistent
"watershed" was observed between HO-1 induction within the cortical tubules and
those of the outer stripe of the medulla. Images taken at high-power reveal the
presence of a number of HO-1 positive interstitial cells in this area. Dual
immunofluoresence with for HO-1 and the macrophage marker CD68 revealed these
cells to be HO-1 positive macrophages (Fig 2.4). No such cells were observed in the
outer stripe of the medulla of PBS treated animals.
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Fig 2.1
Isotype control (renal tissue) - Rabbit serum 1:1000 shows no positive
staining
Normal saline - x20 objective image shows constitutive expression of HO-1
within tubules of the renal cortex
68
HA 30mg/kg - Tubules of the renal cortex stain strongly for HO-1. There is an
abrupt "watershed" effect with minimal staining of tubules of the renal medulla.
Fig 2.2 - HO-1 induction in renal tissue follows a dose response type
relationship to a maximal induction at 30mg/kg. Constitutive expression of the
enzyme is observed in control animals injected with normal saline (Omg/kg).
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Fig 2.3 HA administration induces functional HO-1, with activity levels
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X20 objective. Following HA administration (30mg/kg). HO-1 expression is
localised to the tubules of the cortex. HO-1 is not expressed by the tubules of
the outer stripe of the medulla or the medulla itself
70
•' * - »






* - * ** • J»®s f t%
* -* * * «Q %
*». -.* *v
I I •• »8 llf fc • »*■ '• * ,







*♦ r *» 53 "*
*v • •% i v





v ®V2§ #•1. * $ «s2 _ « **







\* 4■TjMiHO-1 positive cells
* v f v , * * £*s % I *> »w *#
* %. ^ * %* •v m i • i , i% m <m «/ ' ' >«% a ••-•










« > \ \
* •« «► . * * « md*
+ 'tf
X200 objective. HO-1 positive cells are noted within the interstitial spaces, in





Dual immunofluorescence. CD68 labelled with Alexa 488 (Green), HO-1
labelled with Alexa 568 (red). Cells expressing both HO-1 and CD68 are
highlighted in yellow. Implying that these cells are HO-1 positive
macrophages.
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I.V. Heme arginate upregulates functional HO-1 in murine liver 24 hours
post administration
i.v Heme arginate administration resulted in upregulation of HO-1 in liver tissue 24
hours following administration (Fig 2.5). Quantification of this immunostaining by
western blotting shows that, as in renal tissue, this induction followed a "dose
response" type relationship. Maximum HO-1 expression was observed at a dose of
30mg/kg (Fig 2.6). Activity assays confirmed that there was functional upregulation
of HO-1. Maximum activity was observed at a dose of 30mg/kg (93.3 ± 26.7 vs 386.7
± 70.6 bilirubin pmols/mg/hr; Normal saline vs 30mg/kg HA; n=3, p<0.05) (Fig 2.7).
DAB immunohistochemistry suggested that HO-1 induction was concentrated in cells
lying within the sinusoidal spaces. Dual immuofluorescence immunohistochemistry
confirmed that these cells were positive for both CD68 and HO-1 indicating that they
were HO-1 positive Kupffer cells (Fig 2.5). Such cells were not observed in PBS
treated control animals. Sections from the spleens of HA treated animals also appear
to show an increase in the numbers of HO-1 positive cells compared to sections from
control animals. This increase occurred particularly within para-follicular areas,
which are commonly populated by macrophages and T cells (Fig 2.8).
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Fig 2.5
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Normal saline - x20 objective image showing constitutive expression of HO-
1 in cells lying within the sinusoidal spaces
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\ H J>\ - 'Vjr.
HA 30mg/kg - X20 objective showing increased expression of HO-1 in cells
lying within the sinusoidal spaces
HA 30mg/kg - x200 objective showing expression of HO-1 by cells lying
within the sinusoidal spaces. The hepatocytes themselves express little HO-1,
although this may be visual artefact given their greater surface area
74
Dual immunohistochemistry. X20 objective from a mouse injected with
30mg/kg HA. CD68 labelled with Alexa 488 (green), HO-1 labelled with Alexa
568 (red). Counterstained with DAPI. Kuppfer cells expressing both HO-1 and
CD68 are highlighted in yellow and are located in within the perisinusoidal
spaces
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Dual immunohistochemistry. X100 objective. 30mg/kg HA. Cells expressing
HO-1 (red) and CD68 (green) are located within the peri-sinusoidal spaces
mg/kg
Fig 2.6 - HO-1 induction in liver follows a dose response type relationship to a
maximal induction at 30mg/kg. Constitutive expression of the enzyme is
observed in control animals injected with normal saline (Omg/kg).



































Fig 2.7 HA administration induces functional HO-1, with activity levels




200p.L PBS i.v. X100 objective of spleen showing constitutive expression of
HO-1 by lymphoid cells located with para-follicular areas.
78
30 mg/kg HA x20 (above). There is increased expression of HO-1 by cells
located within the splenic white pulp. X200 image (below)
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Spleen X200 objective. Dual immunohistochemistry following 30mg/kg HA.
Cells that co-express HO-1 (red) and CD68 (green) are highlighted by arrows.
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Summary
This experimental data set demonstrates that:
1. HA treatment of mice induces functionally active HO-1 protein in both liver
and kidney tissues. This follows a dose/response type relationship to a
maximum induction at 30mg/kg.
2. Within kidney specimens, HO-1 induction is localised to tubules of the renal
cortex. Tubules within the outer medulla do not express HO-1.
3. HO-1 is expressed by resident macrophages within the outer medulla of the
kidney and Kupffer cells within the liver.
4. HA treatment is well tolerated by mice, with no apparent ill effects up to the
maximum dose used (30mg/kg).
Discussion
Heme oxygenase-1 (HO-1) is a 32kDa enzyme that is induced by a variety of stimuli
which include heme molecules, hypoxia, nitric oxide and endotoxin160. A growing
body of evidence suggests that over-expression of HO-1 may be protective in animal
models of IRI168,169,177'178 and transplantation170,171,179. The majority of such studies
utilise metal protoporphryins as HO-1 inducing agents. These substances have
numerous toxic side effects and are unstable at physiological pH, rendering them
unsuitable for clinical use in humans. By contrast HA is a clinical grade heme
• 180 181
protoporphyrin that is routinely used in the treatment of acute porphyria ' . The
drug is generally well tolerated clinically, although a case report of anaphylaxis that
1 8?
was attributed to HA has been published . The British National Formulary lists the
principal side effects of HA as fever and thrombophlebitis at the injection site. A
recent clinical study has also demonstrated that HA treatment upregulates HO-1 in
healthy human volunteers, providing further validation for its potential use in clinical
•183trials . Only a few in vivo studies that utilise HA have been published, but these
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appear to provide further evidence of the protective benefits of this drug. HA was
shown to improve liver microcirculation and mediated an anti-inflammatory cytokine
• • 184
response in a rat model of simulated haemorrhagic shock . Previous work from our
own group has also shown that HA pre-treatment reduces structural injury and
preserves renal function in aged mice subjected to renal IRI50.
The data set presented in this chapter confirms that HA treatment upregulates
functional HO-1 in a dose response pattern within murine liver and kidney tissue.
Doses up to 30 mg/kg were apparently well tolerated by the animals, with no obvious
adverse side effects or deaths within either the treatment or control groups. 30mg/kg
was selected for the purposes of further in vivo experimentation given the maximal
induction of HO-1 at this dosage. The patterns of HO-1 expression that were
observed in renal tissue are of particular interest. An abrupt "watershed'" in the
staining was consistently noted. The tubules of the renal cortex strongly expressed
HO-1, in contrast to those of the medulla and the outer stripe of the medulla (OSOM),
which did not. Potential explanations for this pattern of HO-1 expression might be
found in renal vascular physiology. Tubules in the renal cortex are exposed to higher
initial concentrations of HA within the vascular supply. They receive their blood
supply from the proximal part of the efferent arterioles that form immediately after
the circulation of blood through the glomeruli. There may therefore be an insufficient
concentration of HA remaining within the more distal efferent arterioles that supply
the tubules of the OSOM to enable significant HO-1 induction. At high magnification
however, we did observe a population of HO-1 positive cells in the OSOM following
HA administration. These cells were found in close physical proximity to the tubules
of this region that did not express HO-1. Co-expression of CD68 and HO-1 by
immunofluorescence indicates that these cells were HO-1 positive macrophages.
Should HA administration prove to be protective in these models, the absence of HO-
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1 positivity in the tubules of the OSOM would suggest that direct tubular expression
of HO-1 might play a less important role within that mechanism than other factors.
Some similarities were noted between the HO-1 staining pattern observed in the liver
following HA administration and those in the kidney. Numerous HO-1 positive cells
were identified within liver sinusoids, whereas hepatocytes by comparison expressed
apparently little HO-1. Dual immunohistochemistry for CD68 and HO-1 confirmed
that these cells were in fact HO-1 positive Kupffer cells (tissue resident macrophages).
It is worth noting that the concentration of DAB in macrophages within the relatively
small space represented by a single macrophage (in comparison to the much larger
hepatocytes) may give the appearance of more intense HO-1 expression. The
hepatocytes themselves may in fact contain increased absolute levels of the enzyme,
yet distributed over a much wider area, giving the impression of less intense HO-1
staining. The findings in this study are in keeping with those of other authors. Devey
et al have reported Kupffer cells to be the principal site of HO-1 expression in the
267liver . These authors selectively depleted Kupffer cells and circulating monocytes in
a model of hepatic ischaemia reperfusion injury that was based upon the CD1 lb DTR
mouse. They noted that deletion of these cells rendered mice highly susceptible to
hepatic IRI and concluded that tissue resident macrophages protected the liver from
IRI via a HO-1 dependent mechanism. Such findings may be of relevance within our
own models of native kidney IRI, and isograft transplantation, given the absence of
HO-1 expression within the tubules of the outer medulla, and the observation that
HO-1 positive macrophages are present at this site 24 hours after HA administration.
The sections from the spleens of HA-treated mice showed a pattern of HO-1
expression that was predominantly within the parafollicular areas. Some of these cells
were also found to be co-positive for CD68 and HO-1, suggesting HO-1 expression
by splenic macrophages, in keeping with the findings in liver and renal tissue. Given
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the para-follicular location of the HO-1 positive cells, it is possible that some of the
expression may also be by T-cells. It is established that HO-1 induction has an
immunosuppressant action268 and has been shown to inhibit the differentiation and
proliferation of cytotoxic T cells, whilst prolonging the survival of cardiac
9AQ
allografts . Further immunophenotyping to clarify precisely which cell subtypes
express HO-1 within the spleen may be of value, particularly with reference to the
potential use of this drug in renal allograft transplantation.
This study consistently demonstrates HO-1 expression by macrophages in liver, renal
and splenic tissue following HA administration. However, it was less clear whether
HO-1 was expressed directly by endothelial cells within the microvasculature. The
pattern of HO-1 positivity within the liver and the outer medulla of the kidney was not
consistent with HO-1 expression by endothelial cells in these organs. This observation
is in keeping with the published literature. Whilst HO-1 induction is reported in
cultured endothelial cells in vitro 270, 11, localisation of HO-1 expression to the
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endothelium in vivo is less consistently observed ' . This may reflect differences
in the HO-1 inducing agents used between studies, as well as a variety of other factors.
For example, Ali et al235 noted that HO-1 expression by vascular endothelium
following statin administration was enhanced following exposure to laminar sheer
stress and impaired by disturbed flow. Such variables may account for some of the
differences within published accounts. It is also possible that immunohistochemistry
may not be sufficiently sensitive to highlight HO-1 expression by the endothelial cells
of the peri-tubular capillary network. These cells are of low volume and have a
flattened shape; patchy HO-1 positivity distributed throughout such a cell might
therefore be rather indistinct. Laser micro dissection techniques or flow cytometry
may help to clarify whether these cells do upregulate HO-1 in response to HA
administration. However, if HO-1 is not expressed by the tubules of this region, it is
plausible that there may similarly be little or no expression of HO-1 by the
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microvasculature in the same site. The physiological explanation suggested earlier,
with reference to the tubules of the OSOM may also be relevant in the case of
endothelial cells. Whilst preservation of the microvasculature may ultimately prove to
be critical to HA mediated protection in IRI, that protection need not necessarily be
via direct expression of the enzyme by the endothelium. Rather, the effects of the
systemic induction of HO-1 upon the preservation of renal blood flow and
improvements in renal haemodynamics may prove to be more important than the
limitation of endothelial cell loss. Renal haemodynamics have been shown to be
impaired following renal ischaemia in HO-1 knockout mice when compared with wild
type controls274. Some authors have also noted a significant enlargement of the
vascular diameter and an increase in capillary blood flow in transplanted kidneys
following treatment with the HO-1 inducer hemin199. It would be interesting to
evaluate similar parameters in mice following HO-1 induction by HA through the use
of intra-vital microscopy or a similar imaging technique. The alterations in renal
haemodynamics that have been described may be related to CO production as a bi-
product of haem catabolism by HO-1. CO is thought to mediate some of the
protective benefits of HO-1 through inhibition of platelet aggregation275 and increased
vasodilatation173. Both of these phenomena would enhance organ perfusion and
therefore reduce ongoing ischaemic damage. Attempts were made to measure
carboxyhaemoglobin levels in the blood of these HA treated animals but
unfortunately proved unsuccessful. This was probably due to inadequate sensitivity of
the clinical blood gas analyser used. The HO-1 activity in the dose response
experiments outlined in this chapter was measured in units of pg of bilirubin formed
per mg protein per hour i.e. in minute quantities. However, given that this series of
experiments has shown increased functional activity of HO-1 and a measured increase
in bilirubin levels, it is reasonable to assume that there will be a similar increase in
CO levels within the tissues.
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Chapter 3: In vivo models of




Data presented In the first chapter of this thesis established that HA pre-treatment
confers protective benefits of upon MCEC-1 cells that were exposed to conditions
which replicate those encountered during IRI in vivo. In chapter 2 it was shown that
HA treatment of mice upregulates functional HO-1 protein in both liver and kidney
specimens and that HO-1 expression within the kidney was localised to tubules of the
renal cortex. The tubules of the medulla, and the outer stripe of the medulla did not
express HO-1 following HA administration. HO-1 positive interstitial macrophages
were identified within this region, in association with these HO-1 negative tubules.
The next phase of experimental work involved determining whether HA treatment can
protect renal structure and function in animal models of native kidney IRI and renal
isograft transplantation. Our in house model of native kidney IRI is well-established50'
and allows for the measurement of postoperative renal function (serum creatinine
levels) in conjunction with quantification of structural injury (ATN score). Our model
of murine renal isograft transplantation is stable and reproducible with a good
technical success rate219' 276. The organ recipient within this model retains a
functioning kidney and therefore measurements of renal function are not relevant.
This model was used to compare HA treatment of the organ donor with treatment of
the organ recipient. Particular reference was given to the structural integrity of the
microvasculature as measured by CD31 immunohistochemistry in both models. The
numbers of HO-1 positive interstitial cells within the outer stripe of the medulla were
quantified prior to and following injury within each system.
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Materials and methods
Murine model of ischaemia reperfusion injury
All mice were males aged 6-8/weeks old, on inbred FVB/nj strain background
purchased from Harlan (UK). Procedures were performed under Home Office
guidelines. Animals received pre-treatment 24 hours prior to surgery with either
200[xl PBS or 200pl of a solution containing 30mg/kg Heme arginate (Normosang;
Leiras Oy Pharmaceuticals, Finland) diluted in PBS. HA solution was administered
via penile vein injection under brief inhalational isofluorane anaesthesia. Anaesthesia
was induced prior to ischaemia/reperfusion injury surgery using Ketamine and
Metatomidine via the intraperitoneal route, with Buprenorphine analgesia
subcutaneously. Via a midline laparotomy a right nephrectomy was performed and
the left renal pedicle identified and clipped using an atraumatic clamp for 20 minutes.
The right nephrectomy specimen was termed "day 0" kidney and was analysed for
HO-1 expression. During the ischaemic period body temperature was maintained at
35°C using a heating blanket with homeostatic control (Harvard Apparatus, Boston
MA) via a rectal temperature probe. The clamp was then removed, the peritoneum
closed with 5/0 suture, the skin closed with clips, and anaesthesia reversed using
atipamazole. 1ml sterile saline was administered subcutaneously prior to and post
surgery. The animals were maintained in an incubator overnight at (27°C), with
further s/c saline given the next morning. Blood and tissue samples were obtained at
24 hours post surgery under terminal anaesthesia. The post ischaemic kidney was
termed "day 1" kidney. The experimental procedure is summarised in Fig 3.1.
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Assessment of renal function
Plasma samples were prepared from whole blood, and measures of serum creatinine
were obtained (in pMol/L) by the Jaffe method (Alpha Laboratories Ltd., UK) on a
Cobas Fara Centrifugal Analyser (Roche Diagnostics, UK) according to the
manufacturer's instructions.
Model of renal isograft transplantation
All mice were males aged 6-8 weeks old on inbred FVB/nj strain background (Harlan,
UK). Procedures were performed under Home Office guidelines. 24 hours prior to
surgery, the mice were anaesthetised transiently with inhalational isofluorane and
treated with 200mL PBS or 30mg/kg Heme arginate (Normosang, Leiras Oy
Pharmaceuticals, Finland) via penile vein injection. Both donor and recipient mice
were administered heparin prior to the transplant surgery. Anaesthesia was induced by
intraperitoneal ketamine (70mg/kg) and medetomidine (l.Omg/kg). Subcutaneous
buprenorphine was administered as an analgesic (0.06mg/kg). Following a midline
laparotomy, the left kidney was isolated on its vascular pedicle and the ureter tied off
and divided close to the bladder. The vena cava and cranial aorta were then tied off.
The caudal aorta was divided and the kidney was perfused with University of
Wisconsin (UW) solution maintained at 4°C. The nephrectomy was completed by
dividing the renal vein, cranial aorta and ureter. The donor kidney was stored in UW
solution at 4°C. Recipient mice underwent a right nephrectomy. Parallel sections of
vena cava and aorta caudal to the left renal pedicle were isolated with arterial clamps.
The renal vein was anastomosed with the vena cava and the renal artery with the aorta
with 11/0 sutures such that the donor kidney lay on the right side. Following removal
of the clamp, the ureter was anastomosed to the bladder using 9/0 sutures and the
peritoneum was then closed with 5/0 suture. The skin was closed with clips.
Anaesthesia was reversed using atipamazole (2mg/kg). Prior and post-surgery, 1 ml
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subcutaneous (s/c) sterile saline was administered. The mice were kept in an incubator
overnight (at 27°C) followed by further s/c saline in the morning. Tissue was
harvested 24 hours after surgery following termination by cervical dislocation. The
animals were kept under close observation post-operatively and culled if recovery was
slow. The technical success rate of the model was 75%, defined as survival to the end
of the experiment and the presence of a viable kidney on completion. The
experimental procedure is summarized in Fig 3.2.
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Fig 3.1 Overview of IRI experiment. Green arrows represent 24 hour time
periods. On day 0 the left kidney is subjected to 20 mins reversible warm
ischaemia following a right nephrectomy (day 0 kidney). 24 hours post
surgery, blood and tissue samples (day 1 kidney) were obtained under
terminal anaesthesia.
Fig 3.2
Day 0: 6 week-old FvB mice are injected with 30mg/kg HA or 200uL PBS i.v. These
animals are either used as donor or recipient animals in subsequent transplant
experiments.
Day 1 kidney
Day 1: 24 hours after pre-treatment of either the donor or recipient, a kidney is
retrieved from the organ donor and implanted into an FvB recipient animal. The
contra-lateral kidney (day 1 kidney) from the donor is analysed to confirm HO-1 up-
regulation. In the recipient treated group, the nephrectomy specimen from the






KT— Transplanted kidney excised for
Vfa histology (Day 2 kidney)
1/4 fixed PFA
1/4 fixed Methocarn
2/4 snap frozen - stored -80°
Day 2: After 24 hours transplanted animals are sacrificed and the post-transplant
kidney (day 2 kidney) is retrieved for analysis.
FIG 3.3: Pre-treatment with HA significantly protects renal structure against
renal IRI (n=8 vs 5, p<0.05).
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Immunohistochemistry and quantification of CD31 staining
Whole kidneys were cut longitudinally and either snap frozen in liquid nitrogen, fixed
in methyl Carnoy's solution (60% methanol, 30% chloroform and 10% acetic acid) or
4% paraformaldehyde prior to embedding in paraffin. 4qm tissue sections were cut
and stained with haematoxylin and eosin for assessment ofmedullary tubular necrosis.
For assessment of CD31 expression, formalin fixed sections were treated in protease
K solution (12.5mg/100ml PBS preheated to 37°C, for 20 minutes at 37°C, Sigma-
Aldrich, Gillingham, UK) and incubated with rat monoclonal antibody (1:10 dilution,
4°C overnight; BD Biosciences Pharmingen, Oxford, UK). This was followed by
biotinylated rabbit anti-rat primary antibody (DakoCytomation, Gostrup, Denmark).
For CD31 immunohistochemistry, 2 drops of HRP rabbit EnVision reagent (Dako UK
limited, Cambridgeshire UK) were added for 30 minutes prior to DAB
counterstaining. FIO-1 expression was assessed following antigen retrieval in citrate
buffer (lOmM sodium citrate, 0.05% tween. Microwaved at 800W for 3 x 5 min).
Sections were then incubated with rabbit anti mouse polyclonal antibody (1/500
dilution; 4°C overnight; Stressgen Biotechnologies, Vancouver, Canada) Renal
macrophages (MO) were identified by immunostaining for the tissue MO marker
F4/80. Methyl Carnoy's fixed tissue was deparaffinized in xylene, rehydrated and
blocked using 3% H2O2 prior to incubation with rat anti-F4/80 monoclonal antibody
(1/250 dilution; Caltag Laboratories, Northampton, UK). Infiltrating neutrophils were
identified by nuclear morphology combined with immunostaining for the Grl
(Ly6c/g) antigen using Rat anti-Grl monoclonal antibody (1/350 dilution; Cambridge
Bioscience, UK). All rat anti-mouse antibodies were incubated at 4°C overnight with
subsequent incubation with mouse-adsorbed biotinylated rabbit anti-rat IgG (1/300
dilution; Vector Laboratories, Peterborough, UK) at room temperature (RT) for 30
minutes. After washing sections were incubated with Vectastain ABC Elite reagent
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(Vector Laboratories, Peterborough, UK) for 30 minutes at RT, prior to washing and
staining with diaminobenzidine (DAB) (Dako UK, Cambridgeshire, UK).
Counterstaining was performed with hematoxylin prior to dehydration and mounting.
In all cases appropriate isotype antibodies were used as negative controls. MO and
neutrophils were identified by morphology and staining pattern, and expressed as
mean cells per x400 microscope field, with 3 fields being assessed per section.
Tubules within the outer stripe of the outer medulla (OSOM) were photographed
using a Leica DC300 digital camera (x50) on a Leica DMLB microscope and tubules
counted as viable and necrotic tubules on the basis of nuclear morphology and
integrity of the epithelial cell layer using ImageJ software (Cell counter plugin;
ImageJ 1.36b; National Institutes of Health, Bethesda, MD;
http://rsb.info.nih.aov/ii/Javal .5.0 13). CD31 immunostaining was quantified from
x400 microscope field images, with 3 fields being captured per section. Subsequent
analysis of the area of DAB positive staining was performed using Colour Range tool
on Photoshop CS3 Extended (Version 10.0.1; Adobe Systems Europe, Uxbridge, UK).
Results were expressed as CD31 positivity as a percentage of total area. All slides and
images were assigned a number to ensure that subsequent analysis was performed in a
blinded fashion, without knowledge of the treatment groups. In the case of the H&E
stained slides used for assessment of tubular necrosis, the blinding process was
performed by a third party in a randomised fashion.
Results
Heme arginate pre-treatment protects renal structure and function
following native kidney IRI
Histological injury was quantified in the outer medulla 24hr following IRI by
counting the percentage of necrotic tubules in high-power fields (X200 objective).
Fields were quantified until the whole of the outer medulla represented in the sections
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had been visualised. Pre-treatment with HA offered significant protection against
acute tubular necrosis when compared with PBS treated animals (Fig 3.3, see page 92.
69.6 ±10.2% vs. 36.5 ± 3.5 %ATN PBS vs. HA; n=8 vs.5, p<0.05). A macroscopic
comparison of a typical post IRI kidney from each group is represented in Fig 3.4.
PBS control kidneys were noticeably more oedematous and haemorrhagic compared
with those from the HA treated group. Typical histological sections from each group
are compared in Fig 3.5. The differences in n number between the two groups was
due to a lack of representation of OSOM within the plane of section in 3 HA treated
animals. HA treated animals also had significant preservation of renal function after
surgery compared with PBS treated controls (Fig 3.6. Serum creatinine 132 ± 44.4 vs
78 ± 24.3pmol/l PBS vs. HA; n=8, p<0.05).
Pre-treatment of the organ donor with Heme arginate protects renal
structure in a model of murine renal isograft transplantation
Histological injury was quantified within the outer medulla 24 hours after isograft
transplantation as previously described. Pre-treatment of donor animals with HA
significantly protected the transplanted kidney against acute tubular necrosis when
compared with PBS treated controls (Fig 3.7. 54.1 ± 9.4% vs. 23.46 ± 7.8% ATN PBS
vs. HA; n=10, p<0.05).
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PBS Control Heme Arginate
Fig 3.4: Typical macroscopic appearance of post IRI kidneys. Specimens
from PBS treated animals were noticeably more haemorrhagic and
oedematous than those of HA treated animals.
HA Rx kidney - day 1 PBS Rx kidney - day 1
Fig 3.5: Comparison of PBS and HA treated kidneys following IRI. Extensive
ATN is observed in the PBS pre-treated kidney, with marked loss of tubular
epithelial cells. There is cast material and debris within many of the tubules
and microscopic evidence of haemorrhage within the tissue. By contrast, the
HA pre-treated kidney has preserved tubules with viable tubular epithelial




Fig 3.6 : Pre-treatment with HA significantly protects renal function against IRI
compared with PBS pre-treated control animals (n=8, p<0.05)
PBS Donor HA Donor
n=10 p<0.05
Fig 3.7. Renal Isograft transplantation: Pre-treatment of the organ donor
with HA results in significantly lower ATN scores compared with PBS pre-
treated control animals following transplantation (n=10, p<0.05)
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Pre-treatment of the organ recipient with Heme arginate offers relative
protection of renal structure in murine renal isograft transplantation
A clear trend toward a reduction in ATN scores was seen in HA treated recipient
animals when compared with their PBS treated counterparts although these
differences did not reach statistical significance in this series of experiments. This is
largely due to the lower ATN scores in the PBS control recipient treated animals
compared with those in the PBS donor treated animals. Reasons for this difference are
unclear. The result may reach statistical significance if additional transplant
experiments are performed. (Fig 3.8. 29.1 ± 8.5% vs. 14.2 ± 4.5% ATN. PBS vs. HA;
n=10, p=0.21).
Pre-treatment with Heme arginate offers relative preservation of the
renal microvasculature following native kidney IRI
Given the marked differences in levels of acute tubular necrosis and renal function,
the integrity of the vascular network was assessed using the endothelial cell marker
CD31. Representative images of CD31 staining within the outer medulla prior to
injury compared with images taken following IRI in HA and PBS treated animals are
seen in Fig 3.9. There was loss of CD31 staining in the outer medulla of PBS treated
animals 24 hours after IRI, although the differences did not reach statistical
significance (Fig 3.10. 15.2 ± 3.5 vs. 8.7 ± 1.3; %OSOM CD31+ve; PBS day 0 vs.
PBS day 1; n=8, p=0.08). CD31 positivity was relatively preserved in HA pre treated
animals after injury by comparison, although this result was not statistically
significant (Fig 3.10. 11.8 ± 2.0 vs. 13.1 ± 2.0; %OSOM CD31+ve; HA day 0 vs. HA




Fig 3.8 Renal isograft transplantation: Pre-treatment of the organ recipient
with HA results in a trend toward lower ATN scores when compared to PBS
treated control animals. This does not reach statistical significance (n=10,
p=0.21)
Fig 3.9
Isotype control. Section of renal cortex incubated with rat igG1, the isotype
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CD31 renal cortex. x20 image from contra-lateral control kidney (day 0 - not
subjected to IRI). CD31 stains glomeruli and the peritubular capillary network.
Peri tubular capillaries
Vasa Recta
CD31 Outer medulla. x20 image from day 0 kidney. CD31 delineates the
intact peritubular capillary network and vasa recta.
CD31 Outer medulla, day 1. PBS pre-treatment: X20 image from the outer
medulla. There is extensive ATN with necrotic tubular debris
CD31 Outer medulla, day 1. PBS pre-treatment: X200 image from the
same slide. The peri-tubular capillary network is clearly disrupted
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CD31 Outer medulla, day 1. HA pre-treatment: By contrast, in this X20
image from the outer medulla of an HA pre-treated animal, there is
preservation of the peri-tubular capillary network.
Fig 3.10. Native kidney IRI: Counts of CD31 positivity by percentage area
taken from the outer medulla in PBS and HA treated animals prior to (day 0)
and following IRI (day 1). There is a clear trend toward loss of CD31 staining
in PBS pre-treated animals, although this does not reach statistical
significance (n=8, p=0.096). By contrast, CD31 positivity remains constant in
the HA treated animals following injury, implying preservation of the
peritubular capillary network.
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Pre-treatment of the organ donor with HA does not protect the renal
microvasculature following renal isograft transplantation
There was a significant loss of CD31 immunostaining in the outer medulla of
recipients whose organ donor was treated with either PBS or HA when compared with
pre-transplantation levels from the donors contralateral kiney (day 1). These results
suggest that HA treatment did not preserve the integrity of the microvasculature in the
HA treatment group, despite the significantly lower ATN scores observed following
HA treatment (Fig 3.11. 25.2 ± 3.7 vs. 12.3 ± 3.7; %OSOM CD31+ve; PBS D1 vs.
PBS D2; n=10, p<0.05. 24.8 ± 2.4 vs. 10.3 ± 2.7; %OSOM CD31+ve; HA D1 vs. HA
D2;n=10, p<0.05).
Recipient animals pre-treated with either HA or PBS have similar CD 31
counts before and after renal isograft transplantation
There were no statistically significant differences in the levels of CD31
immunostaining in the outer medullas of either PBS or HA treated recipient animals
when compared to the levels in the day 1 nephrectomy specimen from the recipient
animal. This result contrasts with the findings in donor animals in that it suggests that
transplantation per se does not result in microvascular injury. Potential explanations
are discussed below (Fig 3.12. 17.4 ± 2.4 vs. 17.7 ± 2.3; %OSOM CD31+ve; PBS D1





Fig 3.11. Donor pre-treated renal isograft transplantation: Significant
reductions in CD31 positivity were seen in both PBS and HA treated donor
animals following transplantation compared with non-transplanted
contralateral control kidneys. This implies that microvascular injury following
transplantation was not modified by HA pre-treatment (n=10, p<0.05 for both
PBS and HA pre-treatment).
n=10
Fig 3.12. Recipient pre-treated renal isograft transplantation: No
significant differences were seen in CD31 counts taken from Pre-treated
recipient animals following renal isograft transplantation when compared with
contralateral control kidneys (day 1) (n=1-, p>0.05 for both PBS and HA pre-
treatment).
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HO-1 positive macrophages are present in the outer stripe of the
medulla of HA treated animals before and after native kidney IRI
Immunohistochemistry showed continued expression of HO-1 by the tubules of the
renal cortex at the conclusion of the experiment on "day 1". As previously noted in
chapter 2, there was minimal expression of HO-1 in the tubules of the outer stripe of
the medulla ofHA pre-treated mice. This is the area maximally affected by IRI. HO-1
positive interstitial cells were detected in this region prior to injury in the HA-treated
group. Dual immunofluorescence confirmed that many of these cells were positive for
both the tissue macrophage marker CD68 and HO-1, implying that they are HO-1
positive macrophages (Fig 3.13). The numbers of these cells tended to increase
following surgery. In PBS pre-treated animals no such cells were seen before IRI;
however multiple HO-1 positive cells were noted 24 hours after surgery even in the
absence of HA administration. (Fig 3.14. Cell counts/hpf; 0 ± 0 vs. 2.0 ± 0.65 PBS DO
vs. PBS D1. 2.6 ± 1.17 vs. 3.8 ± 1.1 HA DO vs. HADl;n=7-10, p<0.05).
HO-1 positive macrophages are present in the outer medulla of HA
treated donor animals before and after renal transplantation
A similar pattern to that seen in native kidney IRI was observed before and after
transplant surgery. HO-1 positive cells were present in the outer medulla of donor
animals treated with HA, and the numbers of these cells were maintained in the post
transplant kidney on day 2. In the PBS control animals HO-1 positive cells were
largely absent in the PBS treated animals on day 1, yet are seen at the conclusion of
the experiment on day 2 even in the absence of HA treatment (Fig 3.15. Cell




X40 image, HA pre-treated animal, day 1 post IRI: Tubules within the renal
cortex continue to express HO-1 at the conclusion of the experiment
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Outer medulla of HA pre-treated mouse, day 1. X100 image: HO-1 positive
interstitial cells are identified in association with viable tubules. Note that the
tubules themselves do not express HO-1
Outer medulla of HA pre-treated mouse, day 1. X200 image. HO-1 positive







Dual Immunohistochemistry confirms the presence of HO-1 expressing
macrophages: In this image from the outer medulla of a HA pre-treated
animal subjected to IRI. CD68 is highlighted in green (Alexa 488), HO-1 is




Fig 3.14. Counts of HO-1 positive interstitial cells before and after renal
IRI: No HO-1 positive cells were identified prior to IRI in PBS treated animals
(day 0). However, even in the absence of HA treatment, HO-1 positive cells
were identified after injury (dayl). In HA treated animals a population of HO-1
positive cells were present prior to IRI (day 0), their numbers tended to
increase after IRI surgery (n=8, p<0.05)
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n=10 p<0.05
Fig 3.15. Counts of HO-1 positive interstitial cells in the outer medulla
following renal isograft transplantation. Donor pre-treatment: Counts of
HO-1 positive cells follow a similar pattern to those observed in renal IRI.
Increased numbers of HO-1+ cells were present after transplantation in PBS
treated donors (day 2) compared with counts from the non-transplanted
contralateral kidney (day 1). In HA treated animals a population of HO-1+ cells
are present prior to injury (day 1) the numbers of these cells increase after
















PBS D1 PBS D2 HAD1
n=10 p<0.05
HA D2
Fig 3.16. Counts of HO-1 positive interstitial cells in the outer medulla
following renal isograft transplantation. Recipient pre-treatment: Counts
of HO-1 positive cells follow a different pattern in recipient animals pre-treated
with HA. The apparent decrease in the numbers of these cells from day 1 to
day 2 reflects the fact that the donor kidney, which has not been exposed to
HA, has been transplanted into an HA treated animal. The small numbers of
HO-1 positive cells present in HA and PBS treated animals on day 2 may
represent recruitment of HO-1 positive monocytes from the recipient's
circulation, or upregulation of HO-1 by tissue resident macrophages within the
transplanted organ itself (n=10, p<0.05)
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HO-1 positive macrophages are not present in the outer medulla of the
post transplant kidney in HA or PBS treated organ recipients
In recipient animals treated with HA, HO-1 positive cells are present before, injury
but their numbers fell significantly following surgery (Fig 3.16, see page 109. Cell
counts/hpf; 0 ± 0 vs. 2.2 ± 1.3 PBS D1 vs. PBS D2. 15.8 ± 3.4 vs. 2.3 ± 0.6 HA D1 vs.
HA D2; n=10, p<0.05). Although the Day 1 kidney has been taken from an animal
that has received HA (the recipient), the post transplant kidney (day 2) originated
from a donor animal that did not receive HA. Therefore, these HO-1 positive cells
have not "disappeared" as such; rather they were never present in the first place. This
result implies a lack of recruitment of HO-1 positive macrophages from the
circulation 24 hours after surgery. This may in part be due to impaired perfusion of
the post-transplant kidney. It may also merely refect the natural history of the chronic
inflammatory process in which macrophages typically enter the tissue space at around
48 hours after injury. Analysis of later time points in this model may be of interest
F4/80 counts show no significant differences before or after surgery in
either native kidney IRI or renal transplantation
There were no significant differences in the numbers of F4/80 positive cells following
IRI (Fig 3.17. Counts of% area/hpf; 10.08 ± 4.6 vs. 2.53 ± 0.75 PBS DO vs. PBS Dl;
5.75 ± 2.84 vs. 4.5 ± 0.9 HA DO vs. HA Dl; n=4-9, p>0.05). There were also no
significant differences in the numbers of F4/80 positive cells pre/post transplantation
in donor pre-treated animals (Fig 3.18. Counts of % area/hpf; 0.64 ± 0.12 vs. 0.9 ±
0.34 PBS Dl vs. PBS D2; 1.46 ± 0.51 vs. 0.81 ± 0.28 HA Dl vs. HA D2; n=10,
p>0.05). Similarly, there were no significant differences in the numbers of F4/80
positive cells in recipient pre-treated animals following transplantation (Fig 3.19.
Counts of% area/hpf; 1.2 ± 0.53 vs. 0.37 ± 0.15 PBS Dl vs. PBS D2; 1.12 ± 0.34 vs.
110
0.84 ±0.18 HA D1 vs. HA D2; n=10, p>0.05). These observations are made despite
the changes in the numbers of HO-1/CD68 co-positive cells in transplantation and
may reflect the fact that HO-1 positive macrophages constitute only certain a
proportion of the total number of F4/80 positive macrophages present in the outer
medulla. No consistent pattern was noted in the F4/80 staining between the
experiments.
An influx of neutrophils was noted in the post ischaemic tissues of
native kidney IRI
Neutrophils were not seen in uninjured renal tissue A significant influx of GR1
positive neutrophils was also noted in the OSOM of both the control and HA treated
animals following IRI surgery. (Fig 3.20, cell counts/hpf 0.0 ± 0.0 vs. 8.22 ± 4.06
PBS DO vs. PBS Dl; 0.34 ± 0.08 vs. 8.87 ± 2.29 HA DO vs. HA Dl; n=7-9 p<0.05).
Neutrophils are associated with acute inflammation and tissue necrosis. Their
presence in association with necrotic tubules is a consistent and expected finding.
Ill
n=4-9 p>0.05
Fig 3.17. Counts of F4/80 positive cells in the outer medulla native
kidney IRI: There are no significant differences in the counts of F4/80 positive
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n=10 p>0.05
Fig 3.18. Counts of F4/80 positive cells in the outer medulla, donor Rx
isograft transplantation: There are no significant differences in the counts of
F4/80 positive cells (mean % area/hpf) before or after transplantation





















Fig 3.19. Counts of F4/80 positive cells in the outer medulla, recipient Rx
isograft transplantation: There are no significant differences in the counts of
F4/80 positive cells (mean % area/hpf) before or after transplantation














PBS DO PBS D1 HA DO HA D1
n=8, p<0.05
Fig 3.20. Counts of GR1 positive cells in the outer medulla native kidney
IRI: A significant increase in the numbers of neutrophils were observed in the
outer medulla of both HA and PBS treated animals following IRI (n=8, p<0.05)
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Summary
The dataset presented in this chapter demonstrates the following key points:
1. HA protects renal structure and function in a murine model ofwarm renal IRI.
2. HA mediated protection in IRI is associated with relative preservation of the
renal microvasculature.
3. HA protects renal tubules, but not the microvasculature, when administered to
donor mice in a model of renal isograft transplantation.
4. HA treatment offers relative protection of renal tubules when administered to
recipient animals in renal isograft transplantation.
5. HA mediated protection is associated with HO-1 positive interstitial cells in
the outer medulla of both IRI and "donor treated" transplants. HO-1 positive
cells were not seen in the outer medulla of "recipient treated" transplants.
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Discussion
These experiments utilise established, stable experimental models of renal IRI50' 67
and renal isograft transplantation219'276 which result in relatively consistent levels of
"J*7'7 77Q
ATN. The severity of Injury in IRI is influenced by variation in temperature " ,
accordingly, uniform experimental conditions were rigorously maintained across all
experimental groups with the use of controlled heating blankets and rectal
temperature probes.
These data demonstrate that HA treatment prior to surgery protects both renal
structure and function in a murine model of native kidney IRI. This work also
suggests that treatment of the organ donor animal is protective against transplant
associated IRI in a murine model of renal isograft transplantation. A clear trend
toward protection following transplantation was also observed in recipient treated
animals, although the differences between the treatment and control groups did not
reach statistical significance. Changes within the structural integrity of the
microvasculature were less consistent. There was a clear trend toward preservation of
the peritubular capillary network within native kidney IRI (as measured by CD31
immunostaining). By contrast, protection of renal tubules within HA treated donor
animals following transplantation was not associated with preservation of the renal
microvasculature. No alterations in the CD31 counts were seen in the recipient treated
animals before and after surgery in HA or control groups. HO-1 positive interstitial
cells were present within the outer medulla prior to injury in HA treated animals
subjected to native kidney IRI. The numbers of these cells were maintained following
surgery. A similar pattern was observed in HA treated donor animals. By contrast, no
such cells were observed in PBS treated controls prior to injury, however a population
of HO-1 positive cells were identified following injury, even in the absence of HA
treatment. Whilst HO-1 positive cells were observed in the nephrectomy specimens
taken from HA treated recipients on day 1, HO-1 positive interstitial cells were not
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observed in the post transplant kidneys of these animals. These findings are discussed
below.
HA treatment protects both renal structure and function following native kidney IRI.
Previous experience from within our group with this model of renal IRI suggests that
preservation of renal function following therapeutic intervention does not always
correlate with reduced tubular injury. Ferenbach et al67 showed that macrophages that
were adenovirally transformed to over-express HO-1 protected renal function in mice
subjected to IRI, despite there being similar levels of ATN in both treatment and
control groups. This latter observation is relevant to one of the central hypotheses to
this thesis. It suggests that whilst the survival of tubular cells is clearly important for
the preservation of renal function following IRI, alternative factors might also be
relevant. As discussed earlier, the effects of IRI upon the renal microvasculature are
profound. The effects of platelet aggregation, vasoconstriction and endothelial
dysfunction may play a critical role in reducing the perfusion of the remaining tubules
following surgery, thereby worsening renal function and potentiating downstream
ischaemic damage194'280. Ferenbach et al observed a reduction in platelet aggregation
in mice injected with HO-1 over-expressing macrophages, and suggest that CO
elaborated as an end product of the reaction catalysed by HO-1 may be responsible for
this effect275. Therefore, preservation of renal function in these animals may be as a
result of enhanced perfusion of the residual tubules.
The in vitro experimental data has demonstrated that HA pre-treatment protects
murine endothelial cells against oxygen and carbon dioxide tensions similar to those
that are encountered during in vivo IRI239. Addition of the specific HO-1 inhibitor
ZNPPiX, abrogated this effect, implying that HO-1 was responsible for this protection.
The effects of HA treatment upon the protection of the renal microvasculature in vivo
were inconsistent. There was a clear trend toward preservation of the renal
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microvasculature in HA treated animals subjected to native kidney IRI. It is inferred
that HO-1 expression is responsible for this although as was noted in the dose
response experiments and in contrast to my in vitro findings, HO-1 expression was
not observed in endothelial cells of the peri-tubular capillary network in vivo. This
observation is in keeping with the findings of other investigators (Mason JC,
unpublished data). In contrast to the findings in native kidney IRI, there was no
protection of the microvascular structure by HA treatment in donor treated animals
following transplantation. CD31 counts in post-transplant, day 2 kidneys from treated
organ donors were significantly reduced in both PBS and HA treatment groups.
Results from the recipient treated transplant series suggested that there was no loss of
CD31 positivity in either the HA or control groups following surgery. This finding
conflicts with the loss of CD31 staining that was observed in native kidney IRI and
donor treated transplantation. CD31 is well recognized as a marker of B-lymphocytes
281 282 283and plasma cells , platelets and megakaryocytes ' and has be found by some
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authors to stain lymphatic vessels " . It seems unlikely that staining of B-
lymphocytes and lymphatics would be a significant source of experimental error.
However, It is possible that platelet aggregation, which is commonplace following
surgical intervention, may have artificially elevated the CD31 count. This may
potentially have given a false impression of microvascular preservation. To avoid this
the photoshop settings were carefully adjusted to minimize background "pickup" and
an identical immunohistochemical protocol was used to that which was employed in
the native kidney IRI and the donor treated transplants. Despite these measures,
artefact may still have been an issue. Attempts were made to use alternative
endothelial markers such as MECA-32, which is reported to have a high specificity
for the endothelium287. Unfortunately, this antibody produced very inconsistent
staining in both fixed and frozen tissue. The staining technique with CD31 was,
however, robust enough to produce meaningful results when used in the native kidney
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IRI model and in donor treated renal isografts, which does suggest that the staining
protocol and quantification method was valid. Alternatively, these results may mean
that that the microvasculature was not significantly injured in either the PBS or HA
treated groups in these experiments. The level of ATN was substantially lower than
that seen in the donor treated transplant series, which supports this theory. These
results as a whole might seem to refute the hypothesis that the maintenance of the
microvasculature is critical to tubular survival, however, effects upon the physical
structure of blood vessels must be considered within the wider context of the
beneficial effects that HO-1 over-expression may have upon a variety of factors that
influence renal haemodynamics such as vasodilatation, platelet aggregation and
endothelial activation. These indices influence both perfusion and leucocyte
infiltration and have been shown to be correlated with beneficial clinical outcomes '
199,200 physical integrity of the microvasculature might not entirely reflect all of
the potentially important changes within the vascular bed. Probing the relative
function of the renal microvasculature would require a multi-modality approach that
utilises emerging imaging techniques such as intra-vital microscopy or laser Doppler
ultrasound scanning.
A consistent finding within our native kidney model of IRI was the presence of HO-1
positive interstitial macrophages within the outer stripe of the medulla, which is the
site of maximal injury following native kidney IRI and transplantation, given its
precarious vascular supply. These HO-1 positive cells were observed prior to IRI in
HA treated animals and their numbers were maintained following surgery. These cells
were also noted following IRI in PBS treated control animals. This may reflect a
response to the ischaemic insult itself, which is a recognised mode of HO-1
induction288. A similar pattern of results was observed in the donor treated transplant
experimental series, in which HA treatment was associated with lower ATN scores.
The potential significance of these HO-1 positive cells is highlighted given that the
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renal tubules of the outer stripe of the medulla do not express HO-1 in response to HA
administration. Previous work from within our group has shown that selective
depletion of macrophages in CDllb DTR mice abrogates the protective benefits of
HA treatment in renal IRJ60, which implies that HO-1 expressing macrophages may
mediate the protective effects of HA. Other authors support this conclusion. HO-1
positive macrophages are reported to mediate some of the protective benefits of
statins in a rat model of renal IRJ224 and depletion of HO-1 expressing macrophages is
222deleterious in hepatic IRI . Furthermore, adenovirally transformed macrophages that
over-express HO-1 home to the site of injury upon re-injection and improve renal
function in a murine model of renal IRI67. Such findings might be explained by the
fact that HO-1 over-expression is thought to induce an anti-inflammatory phenotype
67 251 252within macrophages ' ' . Interestingly, whilst there was a trend toward protection
against ATN in HA treated transplant recipients; the association with the presence of
HO-1 positive cells in the outer medulla was less clear-cut. HO-1 positive cells were
present in the outer medulla of HA treated recipient animals before injury, but the
numbers of these cells were significantly lower after injury. This might suggest an
inability to recruit these cells from the circulation of the HA treated recipient animal,
which may potentially reflect impaired perfusion of the transplanted organ in the
immediate aftermath of surgery. Further mechanistic studies are warranted to clarify
the precise role of HO-1 expressing macrophages in this model and to identify
additional systemic factors that might be responsible for the protective effects of HA
treatment. There was a clear trend toward structural protection in HA treated recipient
animals that did not reach statistical significance. The finding that recipient HO-1
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over-expression is protective is in IRI is not without precedent. Araujo et al
reported that systemic upregulation of HO-1 within recipient animals, rather than
local upregulation of HO-1 within the transplanted organ itself improved cardiac
allograft outcomes in transgenic mice. These authors attributed the differences they
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observed to increased production of carbon monoxide (CO) within the HO-1 over-
expressing recipient animals. Indeed, exogenous administration of low dose CO has
been shown to protect rat lung transplants from IRI via activation of the p38 MAP
kinase pathway and to inhibit progressive chronic allograft nephropathy and restore
renal allograft function290. The finding that HO-1 positive cells were not present
within the outer medulla of HA treated recipient animals suggests that other factors
may be involved in mediating the protection by HA. Increased CO, produced as a
consequence of HO-1 activity, may potentially play a role in the mechanism of
protection observed in HA-treated recipient animals, in particular its effects upon
platelet deposition may be relevant67. However, preliminary attempts to measure CO
levels in the blood ofHA treated mice proved unsuccessful. This may be related to the
sensitivity of the analytical equipment available for use.
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Future work
The significance of these experiments is that they suggest that HA, a drug that is
already clinically licensed and in regular use (albeit for an alternative indication),
might afford protection in when administered to donor animals in models of
transplantation associated IRI. The work also suggests a clear trend toward renal
tubular protection in recipient treated animals. This result may have reached statistical
significance had a larger number of experiments been performed. There are a number
of key limitations of this experimental data that are acknowledged. These issues could
be pursued through additional studies. The data as presented does not definitively
show that HO-1 itself is responsible for HA mediated protection and therefore
repeating this series of experiments with HO-1 "knockout mice" would be an
important experiment to clarity the role of HO-1 in HA mediated protection in vivo.
Furthermore this work does not provide an insight into the fundamental mechanisms
underlying HA mediated protection. I have suggested that the protection may be due
to a modifying action of the drug upon the microvasculature, the renal tubules, HO-1
positive macrophages or a combination of effects upon a variety of these and other
systems, however the results ofmy experiments are rather contradictory in this regard
and I cannot claim to draw any definitive conclusions from my data. My experiments
show no clear-cut association between CD31 counts and ATN score across the native
kidney IRI and isograft transplantation experiments. The microvasculature does
appear relatively preserved following HA administration in native kidney IRI (where
HA protected against ATN) and also in HA treated isograft recipients (where there
was a trend toward structural protection by HA that fell short of statistical
significance). However, HA treated organ donors showed no such preservation of
their microvasculature despite being protected against ATN. Furthermore there was
no consistent pattern in the counts of HO-1 positive macrophages in the outer medulla
when native kidney IRI was compared to donor and recipient treated isograft
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transplantation. The numbers of these cells remained relatively consistent both before
and after surgery in animals that received HA prior to both native kidney IRI and in
HA treated organ donors. The presence of these cells appeared to be associated with
significant protection against ATN in both cases. By contrast, very few HO-1 positive
macrophages were identified in the post transplant kidneys of organ recipients that
received HA pre-treatment prior to surgery. Despite the lack of statistical significance
in the ATN scores in this group when compared to their PBS controls, there did
appear to be a clear trend toward structural protection in these animals. These
inconsistencies suggest that there may be multiple mechanisms involved in mediating
the protection against ATN by HA that may include factors other than those
mentioned here. There may also be different biological mechanisms involved in
systemic treatment when compared to treatment of the organ donor alone. Clarifying
the underlying mechanism would be of interest not only from a scientific perspective,
but may also be of clinical relevance in terms of how this drug may potentially be
administered to transplant patients in the future.
HO-1 positive macrophages
Whilst experiences from within our laboratory group indicate that HO-1 positive
macrophages mediate the protective benefits of HA treatment within murine renal
IRI50, we did not observe HO-1 positive cells within the outer stripe of the medulla of
HA treated recipient animals, although their ATN scores were lower than PBS
controls. The precise origin of these HO-1 positive macrophages following surgical
intervention has also not been definitively determined in either native kidney IRI or
organ donor treated transplants. It is therefore unclear whether they represent tissue
resident macrophages in which upregulation of HO-1 occurs in response to ischaemic
stress, or whether there is recruitment of HO-1 positive monocytes from the animal's
circulation. The capacity to physically dissociate the organ systems, in the context of
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transplantation affords an opportunity to examine this. The use of transgenic,
MacGreen mice in which macrophages are fluorescent291 as either organ donors or
recipients in combination with non-transgenic animals (as either donor or recipient)
might clarify this matter. The lack of HO-1 positive macrophages within the OSOM
of recipient animals suggests that recruitment from the circulation may not occur
following transplantation at the time point we studied (24 hours post surgery). It may
be of value to investigate later time points to see whether such cells are subsequently
recruited to this site. Repetition of these experiments using transgenic CDllb DTR
mice may establish whether HO-1 positive macrophages mediate the beneficial effects
of HA treatment within our transplant model. CDllb-DTR mice (FVB/nj strain) are
transgenic for the human diphtheria toxin receptor gene under the control of the
CD1 lb promoter. Administration of a minute dose of diphtheria toxin results in rapid
ablation of circulating monocytes and resident/infiltrating renal macrophages. Such
mice could be utilised as either organ donors or recipients. Abbrogation of a
protective effect against ATN in mice that were administered HA and diptheria toxin
might imply that macrophages are necessary to mediate the protective ofHA in vivo.
The microvasculature
There are inconsistencies in the pattern of CD31 expression across the series of in
vivo experiments making it difficult to draw definitive conclusions. As indicated
earlier in the discussion, CD31 expression may provide a poor reflection of the range
of changes occurring within the microvasculature and the endothelium following
transplantation or IRI and a multimodality approach that utilises emerging imaging
techniques such as intravital microscopy or infra-red imaging may potentially yield
additionally more relevant data including a real time assessment and quantification of
renal perfusion following surgical intervention66' 292. Staining for CD31 was
performed in the case of both native kidney IRI and transplantation upon kidneys that
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were retrieved 24 hours following surgical intervention. As such, the values obtained
may merely reflect the structural integrity of the whole tissue at this time point.
Clearly, our intention was to draw some mechanistic inferences from the relationship
between tubular preservation and microvascular integrity. It may be of interest to
study the integrity of the microvasculature and tubular injury at earlier time points i.e.
immediately after surgery and for example 2, 4,6 and 8 hours after surgery. From this
it may be possible to infer a relationship between microvascular disruption and
subsequent tubular loss, which might suggest a cause and effect relationship. It would
be intriguing to note whether HA treatment preserves the structure of the peri-tubular
capillary network at such earlier time points.
Molecular mediators
The breakdown products of the reaction catalysed by HO-1 are thought to mediate the
protective benefits attributed to the enzyme . It may therefore be of value to measure
CO levels within mice before and after HA administration. Unfortunately my attempts
to demonstrate a difference the levels found in HA and PBS treated animals were
unsuccessful. I suspect this may reflect a lack of sensitivity on the part of the
laboratory equipment used. Other authors have however measured increased
carboxyhaemoglobin levels in rats in association with HO-1 induction by hemin294.
Repition of these transplants with substitution of the isolated end products of the
reaction that HO-1 catalyses may also clarify mechanism underlying the protection
we observe. Carbon monoxide releasing molecules are commercially available and
have been shown to confer protective benefits in renal IRI248 and as mentioned earlier,
exogenous administration of CO has been shown to be beneficial in animal models of
lung289 and renal transplantation290. It is likely however that the other breakdown
products (biliverdin which is converted to bilirubin and free iron via its depletion and
upregulation of ferrritin) may be involved to in some capacity by modulating a variety
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of additional factors167. Indeed the haemoxygenase system is often thought to have
evolved as defense mechanism due to the pluripotential protective effects against
cellular stress that its breakdown products exert172.
Nitric Oxide (NO)
NO is known to exert a variety of biological effects that may be potentially protective
against IRI which include vasodilatation295, inhibition of endothelin-1 production124'
19°, prevention of leucocyte adherence to endothelium296 and inhibition of platelet
aggregation190. It is possible that increased NO activity may play a role protection
against IRI following HA administration. The L-arginine, to which haem is bound in
HA, is a substrate for nitric oxide synthase and may result in the formation of nitric
oxide (NO)297. Definitive demonstration that HO-1 per se, rather than NO or another
intermediary, is responsible for the protective benefits of HA administration could be
determined by showing a loss of protection associated with HA treatment in
transgenic HO-1 knockout mice following organ transplantation or IRI.
Other future work
From a clinical perspective it may be of obvious interest to evaluate whether a
combination of both donor and recipient treatment with HA might provide any
additional protection from transplant associated IRI. However, treatment of brain-
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stem dead organ donors may raise practical and ethical issues . The transplantation
experiments presented in this thesis have also been performed entirely within an
isograft system. This allows for assessment of the effects of HA treatment upon IRI in
isolation, but does not fully simulate the complex interplay of immune factors that are
encountered within allograft transplants. It may be of interest to repeat these
experiments using mice of different strains to simulate allograft transplantation and
assess the effects of the drug upon acute and chronic rejection. The current work is
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also based largely upon the contention that the initial severity of IRI is associated with
delayed graft function21'22 which is a negative prognostic factor for long-term graft
• 2123 72 • • • •survival ' ' . A single time point of 24 hours following organ transplantation and
native kidney IRI was selected. It would be interesting to assess the effect of HA pre-
treatment upon fibrosis, tubular injury and potentially renal function, in transplanted
organs at longer time-points after surgery. This may provide a more realistic
simulation of the potential benefit of the drug in clinical practice i.e. in reality its main
potential benefit would be to improve the long-term outcome after solid organ
transplantation. However, a remaining viable kidney in the "non-functional" model
described renders measures of serum creatinine non comparable. To date, attempts to
establish a stable, functional model of murine renal transplantation within our
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